000182323912/312023Q3FALSEhttp://fasb.org/us-gaap/2023#PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortizationhttp://fasb.org/us-gaap/2023#PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortizationhttp://fasb.org/us-gaap/2023#OtherAssetsNoncurrenthttp://fasb.org/us-gaap/2023#OtherAssetsNoncurrenthttp://fasb.org/us-gaap/2023#AccruedLiabilitiesCurrenthttp://fasb.org/us-gaap/2023#AccruedLiabilitiesCurrenthttp://fasb.org/us-gaap/2023#OtherLiabilitiesNoncurrenthttp://fasb.org/us-gaap/2023#OtherLiabilitiesNoncurrent00018232392023-01-012023-09-300001823239us-gaap:CommonClassAMember2023-11-01xbrli:shares0001823239us-gaap:CommonClassBMember2023-11-0100018232392023-09-30iso4217:USD00018232392022-12-310001823239us-gaap:NonrelatedPartyMember2023-09-300001823239us-gaap:NonrelatedPartyMember2022-12-310001823239us-gaap:RelatedPartyMember2023-09-300001823239us-gaap:RelatedPartyMember2022-12-310001823239us-gaap:CommonClassAMember2022-12-31iso4217:USDxbrli:shares0001823239us-gaap:CommonClassAMember2023-09-300001823239us-gaap:CommonClassBMember2023-09-300001823239us-gaap:CommonClassBMember2022-12-3100018232392023-07-012023-09-3000018232392022-07-012022-09-3000018232392022-01-012022-09-300001823239us-gaap:CommonStockMemberus-gaap:CommonClassAMember2023-06-300001823239us-gaap:CommonStockMemberus-gaap:CommonClassBMember2023-06-300001823239us-gaap:AdditionalPaidInCapitalMember2023-06-300001823239us-gaap:RetainedEarningsMember2023-06-300001823239us-gaap:NoncontrollingInterestMember2023-06-3000018232392023-06-300001823239us-gaap:CommonStockMemberus-gaap:CommonClassAMember2023-07-012023-09-300001823239us-gaap:AdditionalPaidInCapitalMember2023-07-012023-09-300001823239us-gaap:NoncontrollingInterestMember2023-07-012023-09-300001823239us-gaap:RetainedEarningsMember2023-07-012023-09-300001823239us-gaap:CommonStockMemberus-gaap:CommonClassAMember2023-09-300001823239us-gaap:CommonStockMemberus-gaap:CommonClassBMember2023-09-300001823239us-gaap:AdditionalPaidInCapitalMember2023-09-300001823239us-gaap:RetainedEarningsMember2023-09-300001823239us-gaap:NoncontrollingInterestMember2023-09-300001823239us-gaap:CommonStockMemberus-gaap:CommonClassAMember2022-12-310001823239us-gaap:CommonStockMemberus-gaap:CommonClassBMember2022-12-310001823239us-gaap:AdditionalPaidInCapitalMember2022-12-310001823239us-gaap:RetainedEarningsMember2022-12-310001823239us-gaap:NoncontrollingInterestMember2022-12-310001823239us-gaap:CommonStockMemberus-gaap:CommonClassBMember2023-01-012023-09-300001823239us-gaap:AdditionalPaidInCapitalMember2023-01-012023-09-300001823239us-gaap:NoncontrollingInterestMember2023-01-012023-09-300001823239us-gaap:CommonStockMemberus-gaap:CommonClassAMember2023-01-012023-09-300001823239us-gaap:RetainedEarningsMember2023-01-012023-09-300001823239us-gaap:CommonStockMemberus-gaap:CommonClassAMember2022-06-300001823239us-gaap:CommonStockMemberus-gaap:CommonClassBMember2022-06-300001823239us-gaap:AdditionalPaidInCapitalMember2022-06-300001823239us-gaap:RetainedEarningsMember2022-06-300001823239us-gaap:NoncontrollingInterestMember2022-06-3000018232392022-06-300001823239us-gaap:CommonStockMemberus-gaap:CommonClassAMember2022-07-012022-09-300001823239us-gaap:AdditionalPaidInCapitalMember2022-07-012022-09-300001823239us-gaap:NoncontrollingInterestMember2022-07-012022-09-300001823239us-gaap:RetainedEarningsMember2022-07-012022-09-300001823239us-gaap:CommonStockMemberus-gaap:CommonClassAMember2022-09-300001823239us-gaap:CommonStockMemberus-gaap:CommonClassBMember2022-09-300001823239us-gaap:AdditionalPaidInCapitalMember2022-09-300001823239us-gaap:RetainedEarningsMember2022-09-300001823239us-gaap:NoncontrollingInterestMember2022-09-3000018232392022-09-300001823239us-gaap:CommonStockMemberus-gaap:CommonClassAMember2021-12-310001823239us-gaap:CommonStockMemberus-gaap:CommonClassBMember2021-12-310001823239us-gaap:AdditionalPaidInCapitalMember2021-12-310001823239us-gaap:RetainedEarningsMember2021-12-310001823239us-gaap:NoncontrollingInterestMember2021-12-3100018232392021-12-310001823239us-gaap:CommonStockMemberus-gaap:CommonClassAMember2022-01-012022-09-300001823239us-gaap:AdditionalPaidInCapitalMember2022-01-012022-09-300001823239us-gaap:NoncontrollingInterestMember2022-01-012022-09-300001823239us-gaap:RetainedEarningsMember2022-01-012022-09-300001823239mrvi:MaravaiLifeSciencesHoldingsLLCMember2023-01-012023-09-300001823239mrvi:MaravaiLifeSciencesHoldingsLLCMember2022-01-012022-09-300001823239mrvi:MaravaiLifeSciencesHoldings2LLCMember2023-01-012023-09-300001823239mrvi:MaravaiLifeSciencesHoldings2LLCMember2022-01-012022-09-30mrvi:segment0001823239mrvi:AlphazymeHoldingsIncMember2023-01-222023-01-2200018232392023-01-222023-01-220001823239mrvi:MaravaiLifeSciencesHoldingsIncAndAlphazymeHoldingsIncMember2023-01-222023-01-220001823239mrvi:MaravaiLifeSciencesHoldingsLLCMember2023-01-222023-01-22xbrli:pure0001823239us-gaap:CommonClassBMember2023-01-220001823239mrvi:NucleicAcidProductionSegmentMembersrt:NorthAmericaMember2023-07-012023-09-300001823239srt:NorthAmericaMembermrvi:BiologicsSafetyTestingSegmentMember2023-07-012023-09-300001823239srt:NorthAmericaMember2023-07-012023-09-300001823239mrvi:NucleicAcidProductionSegmentMemberus-gaap:EMEAMember2023-07-012023-09-300001823239us-gaap:EMEAMembermrvi:BiologicsSafetyTestingSegmentMember2023-07-012023-09-300001823239us-gaap:EMEAMember2023-07-012023-09-300001823239mrvi:NucleicAcidProductionSegmentMembersrt:AsiaPacificMember2023-07-012023-09-300001823239mrvi:BiologicsSafetyTestingSegmentMembersrt:AsiaPacificMember2023-07-012023-09-300001823239srt:AsiaPacificMember2023-07-012023-09-300001823239mrvi:NucleicAcidProductionSegmentMembermrvi:LatinAndCentralAmericaMember2023-07-012023-09-300001823239mrvi:LatinAndCentralAmericaMembermrvi:BiologicsSafetyTestingSegmentMember2023-07-012023-09-300001823239mrvi:LatinAndCentralAmericaMember2023-07-012023-09-300001823239mrvi:NucleicAcidProductionSegmentMember2023-07-012023-09-300001823239mrvi:BiologicsSafetyTestingSegmentMember2023-07-012023-09-300001823239mrvi:NucleicAcidProductionSegmentMembersrt:NorthAmericaMember2023-01-012023-09-300001823239srt:NorthAmericaMembermrvi:BiologicsSafetyTestingSegmentMember2023-01-012023-09-300001823239srt:NorthAmericaMember2023-01-012023-09-300001823239mrvi:NucleicAcidProductionSegmentMemberus-gaap:EMEAMember2023-01-012023-09-300001823239us-gaap:EMEAMembermrvi:BiologicsSafetyTestingSegmentMember2023-01-012023-09-300001823239us-gaap:EMEAMember2023-01-012023-09-300001823239mrvi:NucleicAcidProductionSegmentMembersrt:AsiaPacificMember2023-01-012023-09-300001823239mrvi:BiologicsSafetyTestingSegmentMembersrt:AsiaPacificMember2023-01-012023-09-300001823239srt:AsiaPacificMember2023-01-012023-09-300001823239mrvi:NucleicAcidProductionSegmentMembermrvi:LatinAndCentralAmericaMember2023-01-012023-09-300001823239mrvi:LatinAndCentralAmericaMembermrvi:BiologicsSafetyTestingSegmentMember2023-01-012023-09-300001823239mrvi:LatinAndCentralAmericaMember2023-01-012023-09-300001823239mrvi:NucleicAcidProductionSegmentMember2023-01-012023-09-300001823239mrvi:BiologicsSafetyTestingSegmentMember2023-01-012023-09-300001823239mrvi:NucleicAcidProductionSegmentMembersrt:NorthAmericaMember2022-07-012022-09-300001823239srt:NorthAmericaMembermrvi:BiologicsSafetyTestingSegmentMember2022-07-012022-09-300001823239srt:NorthAmericaMember2022-07-012022-09-300001823239mrvi:NucleicAcidProductionSegmentMemberus-gaap:EMEAMember2022-07-012022-09-300001823239us-gaap:EMEAMembermrvi:BiologicsSafetyTestingSegmentMember2022-07-012022-09-300001823239us-gaap:EMEAMember2022-07-012022-09-300001823239mrvi:NucleicAcidProductionSegmentMembersrt:AsiaPacificMember2022-07-012022-09-300001823239mrvi:BiologicsSafetyTestingSegmentMembersrt:AsiaPacificMember2022-07-012022-09-300001823239srt:AsiaPacificMember2022-07-012022-09-300001823239mrvi:NucleicAcidProductionSegmentMembermrvi:LatinAndCentralAmericaMember2022-07-012022-09-300001823239mrvi:LatinAndCentralAmericaMembermrvi:BiologicsSafetyTestingSegmentMember2022-07-012022-09-300001823239mrvi:LatinAndCentralAmericaMember2022-07-012022-09-300001823239mrvi:NucleicAcidProductionSegmentMember2022-07-012022-09-300001823239mrvi:BiologicsSafetyTestingSegmentMember2022-07-012022-09-300001823239mrvi:NucleicAcidProductionSegmentMembersrt:NorthAmericaMember2022-01-012022-09-300001823239srt:NorthAmericaMembermrvi:BiologicsSafetyTestingSegmentMember2022-01-012022-09-300001823239srt:NorthAmericaMember2022-01-012022-09-300001823239mrvi:NucleicAcidProductionSegmentMemberus-gaap:EMEAMember2022-01-012022-09-300001823239us-gaap:EMEAMembermrvi:BiologicsSafetyTestingSegmentMember2022-01-012022-09-300001823239us-gaap:EMEAMember2022-01-012022-09-300001823239mrvi:NucleicAcidProductionSegmentMembersrt:AsiaPacificMember2022-01-012022-09-300001823239mrvi:BiologicsSafetyTestingSegmentMembersrt:AsiaPacificMember2022-01-012022-09-300001823239srt:AsiaPacificMember2022-01-012022-09-300001823239mrvi:NucleicAcidProductionSegmentMembermrvi:LatinAndCentralAmericaMember2022-01-012022-09-300001823239mrvi:LatinAndCentralAmericaMembermrvi:BiologicsSafetyTestingSegmentMember2022-01-012022-09-300001823239mrvi:LatinAndCentralAmericaMember2022-01-012022-09-300001823239mrvi:NucleicAcidProductionSegmentMember2022-01-012022-09-300001823239mrvi:BiologicsSafetyTestingSegmentMember2022-01-012022-09-300001823239mrvi:MaravaiTopcoHoldingsLLCMember2023-09-300001823239mrvi:MaravaiTopcoHoldingsLLCMembermrvi:MaravaiLifeSciencesHoldingsLLCMember2023-09-300001823239mrvi:MaravaiLifeSciencesHoldingsLLCMembermrvi:MaravaiTopcoHoldingsLLCMembermrvi:TaxDistributionMember2023-01-012023-09-300001823239mrvi:MaravaiLifeSciencesHoldingsLLCMembermrvi:MaravaiTopcoHoldingsLLCMembermrvi:TaxDistributionMember2022-07-012022-09-300001823239mrvi:MaravaiLifeSciencesHoldingsLLCMembermrvi:MaravaiTopcoHoldingsLLCMembermrvi:TaxDistributionMember2022-01-012022-09-300001823239mrvi:MaravaiLifeSciencesHoldingsLLCMembermrvi:MaravaiTopcoHoldingsLLCMembermrvi:TaxDistributionMember2023-07-012023-09-300001823239mrvi:NacalaiUSAIncMemberus-gaap:CustomerConcentrationRiskMemberus-gaap:RevenueFromContractWithCustomerMember2023-07-012023-09-300001823239mrvi:NacalaiUSAIncMemberus-gaap:CustomerConcentrationRiskMemberus-gaap:RevenueFromContractWithCustomerMember2023-01-012023-09-300001823239mrvi:NacalaiUSAIncMemberus-gaap:CustomerConcentrationRiskMembermrvi:AccountsReceivableBenchmarkMember2023-01-012023-09-300001823239mrvi:NacalaiUSAIncMemberus-gaap:CustomerConcentrationRiskMembermrvi:AccountsReceivableBenchmarkMember2022-01-012022-12-310001823239us-gaap:CustomerConcentrationRiskMemberus-gaap:RevenueFromContractWithCustomerMembermrvi:BioNTechSEMember2022-07-012022-09-300001823239us-gaap:CustomerConcentrationRiskMemberus-gaap:RevenueFromContractWithCustomerMembermrvi:BioNTechSEMember2022-01-012022-09-300001823239us-gaap:CustomerConcentrationRiskMembermrvi:BioNTechSEMembermrvi:AccountsReceivableBenchmarkMember2022-01-012022-12-310001823239us-gaap:CustomerConcentrationRiskMemberus-gaap:RevenueFromContractWithCustomerMembermrvi:PfizerIncMember2022-07-012022-09-300001823239us-gaap:CustomerConcentrationRiskMemberus-gaap:RevenueFromContractWithCustomerMembermrvi:PfizerIncMember2022-01-012022-09-300001823239us-gaap:CustomerConcentrationRiskMembermrvi:PfizerIncMembermrvi:AccountsReceivableBenchmarkMember2022-01-012022-12-310001823239us-gaap:CustomerConcentrationRiskMembermrvi:AccountsReceivableBenchmarkMembermrvi:CureVacMember2022-01-012022-12-310001823239mrvi:AlphazymeLLCMember2023-01-182023-01-180001823239mrvi:AlphazymeLLCMember2023-01-012023-09-300001823239mrvi:AlphazymeLLCMember2023-07-012023-09-300001823239mrvi:AlphazymeLLCMember2023-01-182023-06-300001823239mrvi:AlphazymeLLCMember2023-04-012023-06-300001823239mrvi:AlphazymeLLCMembermrvi:SecuritiesPurchaseAgreementMaximumPerformancePaymentMember2023-01-180001823239mrvi:SecuritiesPurchaseAgreementRetentionPaymentMember2023-01-180001823239mrvi:AlphazymeLLCMembermrvi:MyChemLegacyOwnersMember2023-01-182023-01-180001823239mrvi:AlphazymeLLCMembermrvi:SecuritiesPurchaseAgreementRetentionPaymentMembermrvi:MyChemLegacyOwnersMemberus-gaap:ResearchAndDevelopmentExpenseMember2023-07-012023-09-300001823239mrvi:AlphazymeLLCMembermrvi:SecuritiesPurchaseAgreementRetentionPaymentMembermrvi:MyChemLegacyOwnersMemberus-gaap:ResearchAndDevelopmentExpenseMember2023-01-012023-09-300001823239mrvi:AlphazymeLLCMember2023-01-180001823239mrvi:MyChemLLCMember2023-07-012023-09-300001823239mrvi:PotentialWorkingCapitalAdjustmentsMembermrvi:AlphazymeLLCMember2023-01-180001823239mrvi:AlphazymeLLCMembermrvi:SecureRepresentationsAndWarrantiesMember2023-01-180001823239mrvi:PotentialWorkingCapitalAdjustmentsMembermrvi:AlphazymeLLCMember2023-04-012023-06-300001823239mrvi:AlphazymeLLCMemberus-gaap:TradeNamesMember2023-01-180001823239mrvi:AlphazymeLLCMemberus-gaap:TradeNamesMember2023-01-182023-01-180001823239mrvi:AlphazymeLLCMemberus-gaap:DevelopedTechnologyRightsMember2023-01-180001823239mrvi:AlphazymeLLCMemberus-gaap:DevelopedTechnologyRightsMember2023-01-182023-01-180001823239mrvi:AlphazymeLLCMemberus-gaap:CustomerRelationshipsMember2023-01-180001823239mrvi:AlphazymeLLCMemberus-gaap:CustomerRelationshipsMember2023-01-182023-01-180001823239mrvi:AlphazymeLLCMemberus-gaap:ValuationTechniqueDiscountedCashFlowMembersrt:MinimumMembermrvi:MeasurementInputRevenueGrowthRateMember2023-01-180001823239mrvi:AlphazymeLLCMemberus-gaap:ValuationTechniqueDiscountedCashFlowMembersrt:MaximumMembermrvi:MeasurementInputRevenueGrowthRateMember2023-01-180001823239mrvi:AlphazymeLLCMemberus-gaap:ValuationTechniqueDiscountedCashFlowMemberus-gaap:MeasurementInputDiscountRateMember2023-01-180001823239mrvi:AlphazymeLLCMemberus-gaap:ValuationTechniqueDiscountedCashFlowMembermrvi:MeasurementInputObsolescentCurveMember2023-01-180001823239mrvi:MyChemLLCMember2022-01-272022-01-270001823239mrvi:MyChemLLCMember2022-01-012022-09-300001823239mrvi:MyChemLLCMember2022-01-272022-11-300001823239mrvi:MyChemLLCMember2022-11-012022-11-300001823239mrvi:MyChemLLCMembermrvi:SecuritiesPurchaseAgreementMaximumPerformancePaymentMember2022-01-270001823239mrvi:MyChemLLCMembermrvi:SecuritiesPurchaseAgreementRetentionPaymentMember2022-01-27mrvi:employee0001823239mrvi:MyChemLLCMembermrvi:MyChemLegacyOwnersMember2022-01-272022-01-270001823239mrvi:MyChemLLCMemberus-gaap:CostOfSalesMembermrvi:SecuritiesPurchaseAgreementRetentionPaymentMembermrvi:MyChemLegacyOwnersMember2023-07-012023-09-300001823239mrvi:MyChemLLCMemberus-gaap:CostOfSalesMembermrvi:SecuritiesPurchaseAgreementRetentionPaymentMembermrvi:MyChemLegacyOwnersMember2023-01-012023-09-300001823239mrvi:MyChemLLCMembermrvi:SecuritiesPurchaseAgreementRetentionPaymentMembermrvi:MyChemLegacyOwnersMemberus-gaap:ResearchAndDevelopmentExpenseMember2023-07-012023-09-300001823239mrvi:MyChemLLCMembermrvi:SecuritiesPurchaseAgreementRetentionPaymentMembermrvi:MyChemLegacyOwnersMemberus-gaap:ResearchAndDevelopmentExpenseMember2023-01-012023-09-300001823239mrvi:MyChemLLCMembermrvi:SecuritiesPurchaseAgreementRetentionPaymentMembermrvi:MyChemLegacyOwnersMemberus-gaap:ResearchAndDevelopmentExpenseMember2022-07-012022-09-300001823239mrvi:MyChemLLCMembermrvi:SecuritiesPurchaseAgreementRetentionPaymentMembermrvi:MyChemLegacyOwnersMemberus-gaap:ResearchAndDevelopmentExpenseMember2022-01-012022-09-300001823239mrvi:MyChemLLCMembermrvi:SecuritiesPurchaseAgreementCompletionOfAcquiredInventoryMember2022-01-270001823239mrvi:MyChemLLCMembermrvi:SecuritiesPurchaseAgreementCompletionOfAcquiredInventoryMember2023-01-282023-01-280001823239mrvi:MyChemLLCMembermrvi:SecuritiesPurchaseAgreementCompletionOfAcquiredInventoryMember2023-01-292023-09-300001823239mrvi:MyChemLLCMember2022-01-270001823239mrvi:MyChemLLCMember2022-10-012022-12-310001823239mrvi:PotentialWorkingCapitalAdjustmentsMembermrvi:MyChemLLCMember2022-01-270001823239mrvi:MyChemLLCMembermrvi:SecureRepresentationsAndWarrantiesMember2022-01-270001823239mrvi:PotentialWorkingCapitalAdjustmentsMembermrvi:MyChemLLCMember2022-10-012022-12-310001823239mrvi:MyChemLLCMembermrvi:SecureRepresentationsAndWarrantiesMember2023-01-282023-03-310001823239mrvi:MyChemLLCMembermrvi:IndemnificationOfPreClosingLiabilitiesMember2023-01-292023-09-300001823239mrvi:MyChemLLCMemberus-gaap:TradeNamesMember2022-01-270001823239mrvi:MyChemLLCMemberus-gaap:TradeNamesMember2022-01-272022-01-270001823239mrvi:MyChemLLCMemberus-gaap:DevelopedTechnologyRightsMember2022-01-270001823239mrvi:MyChemLLCMemberus-gaap:DevelopedTechnologyRightsMember2022-01-272022-01-270001823239mrvi:MyChemLLCMemberus-gaap:CustomerRelationshipsMember2022-01-270001823239mrvi:MyChemLLCMemberus-gaap:CustomerRelationshipsMember2022-01-272022-01-270001823239mrvi:MyChemLLCMemberus-gaap:ValuationTechniqueDiscountedCashFlowMembersrt:MinimumMembermrvi:MeasurementInputRevenueGrowthRateMember2022-01-270001823239mrvi:MyChemLLCMemberus-gaap:ValuationTechniqueDiscountedCashFlowMembersrt:MaximumMembermrvi:MeasurementInputRevenueGrowthRateMember2022-01-270001823239mrvi:MyChemLLCMemberus-gaap:ValuationTechniqueDiscountedCashFlowMemberus-gaap:MeasurementInputDiscountRateMember2022-01-270001823239mrvi:MyChemLLCMemberus-gaap:ValuationTechniqueDiscountedCashFlowMembermrvi:MeasurementInputObsolescentCurveMembersrt:MinimumMember2022-01-270001823239mrvi:MyChemLLCMemberus-gaap:ValuationTechniqueDiscountedCashFlowMembersrt:MaximumMembermrvi:MeasurementInputObsolescentCurveMember2022-01-27mrvi:reporting_unit00018232392022-01-012022-12-310001823239mrvi:NucleicAcidProductionSegmentMember2022-01-012022-12-310001823239mrvi:NucleicAcidProductionSegmentMember2022-12-310001823239mrvi:BiologicsSafetyTestingSegmentMember2022-12-310001823239mrvi:NucleicAcidProductionSegmentMember2023-09-300001823239mrvi:BiologicsSafetyTestingSegmentMember2023-09-300001823239srt:MinimumMember2023-09-300001823239srt:MaximumMember2023-09-300001823239us-gaap:TradeNamesMember2023-09-300001823239srt:MinimumMemberus-gaap:TradeNamesMember2023-09-300001823239srt:MaximumMemberus-gaap:TradeNamesMember2023-09-300001823239us-gaap:TechnologyBasedIntangibleAssetsMember2023-09-300001823239us-gaap:TechnologyBasedIntangibleAssetsMembersrt:MinimumMember2023-09-300001823239us-gaap:TechnologyBasedIntangibleAssetsMembersrt:MaximumMember2023-09-300001823239us-gaap:CustomerRelationshipsMember2023-09-300001823239srt:MinimumMemberus-gaap:CustomerRelationshipsMember2023-09-300001823239srt:MaximumMemberus-gaap:CustomerRelationshipsMember2023-09-300001823239us-gaap:TradeNamesMember2022-12-310001823239srt:MinimumMemberus-gaap:TradeNamesMember2022-12-310001823239srt:MaximumMemberus-gaap:TradeNamesMember2022-12-310001823239us-gaap:TechnologyBasedIntangibleAssetsMember2022-12-310001823239us-gaap:TechnologyBasedIntangibleAssetsMembersrt:MinimumMember2022-12-310001823239us-gaap:TechnologyBasedIntangibleAssetsMembersrt:MaximumMember2022-12-310001823239us-gaap:CustomerRelationshipsMember2022-12-310001823239srt:MinimumMemberus-gaap:CustomerRelationshipsMember2022-12-310001823239srt:MaximumMemberus-gaap:CustomerRelationshipsMember2022-12-310001823239mrvi:AlphazymeLLCMember2023-03-310001823239us-gaap:CostOfSalesMember2023-07-012023-09-300001823239us-gaap:CostOfSalesMember2023-01-012023-09-300001823239us-gaap:CostOfSalesMember2022-07-012022-09-300001823239us-gaap:CostOfSalesMember2022-01-012022-09-300001823239us-gaap:SellingGeneralAndAdministrativeExpensesMember2023-07-012023-09-300001823239us-gaap:SellingGeneralAndAdministrativeExpensesMember2023-01-012023-09-300001823239us-gaap:SellingGeneralAndAdministrativeExpensesMember2022-07-012022-09-300001823239us-gaap:SellingGeneralAndAdministrativeExpensesMember2022-01-012022-09-300001823239us-gaap:FairValueMeasurementsRecurringMemberus-gaap:MoneyMarketFundsMemberus-gaap:FairValueInputsLevel1Member2023-09-300001823239us-gaap:FairValueMeasurementsRecurringMemberus-gaap:MoneyMarketFundsMemberus-gaap:FairValueInputsLevel2Member2023-09-300001823239us-gaap:FairValueMeasurementsRecurringMemberus-gaap:MoneyMarketFundsMemberus-gaap:FairValueInputsLevel3Member2023-09-300001823239us-gaap:FairValueMeasurementsRecurringMemberus-gaap:MoneyMarketFundsMember2023-09-300001823239us-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel1Memberus-gaap:InterestRateCapMember2023-09-300001823239us-gaap:FairValueMeasurementsRecurringMemberus-gaap:InterestRateCapMemberus-gaap:FairValueInputsLevel2Member2023-09-300001823239us-gaap:FairValueMeasurementsRecurringMemberus-gaap:InterestRateCapMemberus-gaap:FairValueInputsLevel3Member2023-09-300001823239us-gaap:FairValueMeasurementsRecurringMemberus-gaap:InterestRateCapMember2023-09-300001823239us-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel1Member2023-09-300001823239us-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel2Member2023-09-300001823239us-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel3Member2023-09-300001823239us-gaap:FairValueMeasurementsRecurringMember2023-09-300001823239us-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel1Memberus-gaap:InterestRateCapMember2022-12-310001823239us-gaap:FairValueMeasurementsRecurringMemberus-gaap:InterestRateCapMemberus-gaap:FairValueInputsLevel2Member2022-12-310001823239us-gaap:FairValueMeasurementsRecurringMemberus-gaap:InterestRateCapMemberus-gaap:FairValueInputsLevel3Member2022-12-310001823239us-gaap:FairValueMeasurementsRecurringMemberus-gaap:InterestRateCapMember2022-12-310001823239mrvi:AlphazymeLLCMemberus-gaap:MeasurementInputDiscountRateMember2023-01-18mrvi:payment0001823239mrvi:MyChemLLCMemberus-gaap:MeasurementInputDiscountRateMember2022-01-270001823239mrvi:MyChemLLCMember2022-04-012022-06-300001823239mrvi:MyChemLLCMember2022-01-012022-12-310001823239mrvi:SanDiegoCaliforniaMember2022-05-31mrvi:building0001823239mrvi:CooperativeAgreementMember2022-05-012022-05-310001823239mrvi:CooperativeAgreementMember2022-05-310001823239mrvi:CooperativeAgreementMember2023-07-012023-09-300001823239mrvi:CooperativeAgreementMember2023-01-012023-09-300001823239mrvi:CooperativeAgreementMember2023-09-300001823239mrvi:JupiterFloridaMember2023-01-31mrvi:extension_option0001823239mrvi:SanDiegoCaliforniaFlandersIIMember2023-06-300001823239mrvi:SanDiegoCaliforniaFlandersIMember2023-03-310001823239mrvi:NewCreditAgreementMemberus-gaap:LineOfCreditMemberus-gaap:SecuredDebtMember2020-10-310001823239us-gaap:RevolvingCreditFacilityMembermrvi:NewCreditAgreementMemberus-gaap:LineOfCreditMember2020-10-310001823239mrvi:NewCreditAgreementMemberus-gaap:LineOfCreditMemberus-gaap:SecuredDebtMember2023-09-300001823239us-gaap:LetterOfCreditMembermrvi:NewCreditAgreementMemberus-gaap:LineOfCreditMember2020-10-310001823239us-gaap:LetterOfCreditMembermrvi:NewCreditAgreementMemberus-gaap:LineOfCreditMember2023-09-300001823239mrvi:NewCreditAgreementMemberus-gaap:SecuredDebtMember2022-01-012022-01-310001823239mrvi:NewCreditAgreementMember2022-01-012022-01-310001823239mrvi:NewCreditAgreementMember2022-01-012022-03-31mrvi:loan0001823239mrvi:NewCreditAgreementMemberus-gaap:LineOfCreditMemberus-gaap:SecuredDebtMember2022-01-310001823239us-gaap:RevolvingCreditFacilityMembermrvi:NewCreditAgreementMemberus-gaap:LineOfCreditMember2023-09-300001823239srt:MaximumMembermrvi:NewCreditAgreementMemberus-gaap:LineOfCreditMemberus-gaap:SecuredDebtMember2023-09-300001823239mrvi:NewCreditAgreementMembersrt:MinimumMemberus-gaap:LineOfCreditMemberus-gaap:SecuredDebtMember2023-09-300001823239us-gaap:InterestRateCapMember2021-03-310001823239us-gaap:InterestRateCapMember2022-05-310001823239us-gaap:InterestRateCapMember2023-09-300001823239mrvi:NewCreditAgreementMemberus-gaap:LineOfCreditMemberus-gaap:SecuredDebtMember2022-12-310001823239us-gaap:RevolvingCreditFacilityMembermrvi:NewCreditAgreementMemberus-gaap:LineOfCreditMember2022-12-310001823239us-gaap:RestrictedStockUnitsRSUMember2023-07-012023-09-300001823239us-gaap:RestrictedStockUnitsRSUMember2022-07-012022-09-300001823239us-gaap:RestrictedStockUnitsRSUMember2023-01-012023-09-300001823239us-gaap:RestrictedStockUnitsRSUMember2022-01-012022-09-300001823239us-gaap:EmployeeStockOptionMember2023-07-012023-09-300001823239us-gaap:EmployeeStockOptionMember2022-07-012022-09-300001823239us-gaap:EmployeeStockOptionMember2023-01-012023-09-300001823239us-gaap:EmployeeStockOptionMember2022-01-012022-09-300001823239us-gaap:EmployeeStockMember2023-07-012023-09-300001823239us-gaap:EmployeeStockMember2022-07-012022-09-300001823239us-gaap:EmployeeStockMember2023-01-012023-09-300001823239us-gaap:EmployeeStockMember2022-01-012022-09-300001823239us-gaap:CommonClassBMember2023-07-012023-09-300001823239us-gaap:CommonClassBMember2022-07-012022-09-300001823239us-gaap:CommonClassBMember2023-01-012023-09-300001823239us-gaap:CommonClassBMember2022-01-012022-09-300001823239mrvi:MaravaiTopcoHoldingsLLCMembermrvi:TaxDistributionMember2023-07-012023-09-300001823239mrvi:MaravaiTopcoHoldingsLLCMembermrvi:TaxDistributionMember2023-01-012023-09-300001823239mrvi:MaravaiTopcoHoldingsLLCMembermrvi:TaxDistributionMembermrvi:MaravaiLifeSciencesHoldingsIncMember2023-01-012023-09-300001823239mrvi:MaravaiTopcoHoldingsLLCMembermrvi:TaxDistributionMember2022-07-012022-09-300001823239mrvi:MaravaiTopcoHoldingsLLCMembermrvi:TaxDistributionMembermrvi:MaravaiLifeSciencesHoldingsIncMember2022-07-012022-09-300001823239mrvi:MaravaiTopcoHoldingsLLCMembermrvi:TaxDistributionMember2022-01-012022-09-300001823239mrvi:MaravaiTopcoHoldingsLLCMembermrvi:TaxDistributionMembermrvi:MaravaiLifeSciencesHoldingsIncMember2022-01-012022-09-300001823239us-gaap:RelatedPartyMembermrvi:MLSH1AndMLSH2Membermrvi:TaxReceivableAgreementPaymentsMember2023-09-300001823239us-gaap:RelatedPartyMembermrvi:MLSH1AndMLSH2Membermrvi:TaxReceivableAgreementPaymentsMember2023-01-012023-09-300001823239us-gaap:RelatedPartyMembermrvi:TaxReceivableAgreementInterestPaymentsMembermrvi:MLSH1AndMLSH2Member2023-01-012023-09-300001823239us-gaap:RelatedPartyMembermrvi:MLSH1AndMLSH2Membermrvi:TaxReceivableAgreementPaymentsMember2023-07-012023-09-300001823239us-gaap:RelatedPartyMembermrvi:MLSH1AndMLSH2Membermrvi:TaxReceivableAgreementPaymentsMember2022-07-012022-09-300001823239us-gaap:RelatedPartyMembermrvi:MLSH1AndMLSH2Membermrvi:TaxReceivableAgreementPaymentsMember2022-01-012022-09-300001823239mrvi:NucleicAcidProductionSegmentMemberus-gaap:OperatingSegmentsMember2023-07-012023-09-300001823239mrvi:NucleicAcidProductionSegmentMemberus-gaap:OperatingSegmentsMember2022-07-012022-09-300001823239mrvi:NucleicAcidProductionSegmentMemberus-gaap:OperatingSegmentsMember2023-01-012023-09-300001823239mrvi:NucleicAcidProductionSegmentMemberus-gaap:OperatingSegmentsMember2022-01-012022-09-300001823239us-gaap:OperatingSegmentsMembermrvi:BiologicsSafetyTestingSegmentMember2023-07-012023-09-300001823239us-gaap:OperatingSegmentsMembermrvi:BiologicsSafetyTestingSegmentMember2022-07-012022-09-300001823239us-gaap:OperatingSegmentsMembermrvi:BiologicsSafetyTestingSegmentMember2023-01-012023-09-300001823239us-gaap:OperatingSegmentsMembermrvi:BiologicsSafetyTestingSegmentMember2022-01-012022-09-300001823239us-gaap:OperatingSegmentsMember2023-07-012023-09-300001823239us-gaap:OperatingSegmentsMember2022-07-012022-09-300001823239us-gaap:OperatingSegmentsMember2023-01-012023-09-300001823239us-gaap:OperatingSegmentsMember2022-01-012022-09-300001823239us-gaap:IntersegmentEliminationMember2023-07-012023-09-300001823239us-gaap:IntersegmentEliminationMember2022-07-012022-09-300001823239us-gaap:IntersegmentEliminationMember2023-01-012023-09-300001823239us-gaap:IntersegmentEliminationMember2022-01-012022-09-300001823239us-gaap:EmployeeSeveranceMembersrt:ScenarioForecastMember2023-11-30

Table of Contents
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 10-Q
QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
For the quarterly period ended September 30, 2023
OR
TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
Commission file number 001-39725
Maravai LifeSciences Holdings, Inc.
(Exact name of registrant as specified in its charter)
Delaware85-2786970
(State or other jurisdiction of incorporation or organization)(I.R.S. Employer Identification No.)
10770 Wateridge Circle, Suite 200
San Diego, California
92121
(Address of principal executive offices)
(Zip code)
______________________________
Registrant’s telephone number, including area code: (858) 546-0004
______________________________
Securities registered pursuant to Section 12(b) of the Act:
Title of each classTrading Symbol(s)Name of each exchange on which registered
Class A common stock, $0.01 par valueMRVIThe Nasdaq Stock Market LLC

Indicate by check mark whether the registrant: (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports); and (2) has been subject to such filing requirements for the past 90 days.    Yes  x    No  o
Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). Yes ☒ No ☐
Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer” and “smaller reporting company” in Rule 12b-2 of the Exchange Act. (Check one):
Large accelerated filerýAccelerated filer
o
Non-accelerated filer
o
Smaller reporting company
o
Emerging growth company
o
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. o
Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Act).     Yes    No  x
As of November 1, 2023, 132,188,632 shares of the registrant’s Class A common stock were outstanding and 119,094,026 shares of the registrant’s Class B common stock were outstanding.
1


Table of Contents
TABLE OF CONTENTS
Page

2


Table of Contents
SPECIAL NOTE REGARDING FORWARD-LOOKING STATEMENTS
This Quarterly Report on Form 10-Q contains “forward-looking statements” within the meaning of the U.S. Private Securities Litigation Reform Act of 1995. All statements other than statements of historical fact included in this report, including, without limitation, statements under the section “Management’s Discussion and Analysis of Financial Condition and Results of Operations,” are forward-looking statements. Forward-looking statements give our current expectations and projections relating to our financial condition, results of operations, plans, objectives, future performance and business. You can identify forward-looking statements by the fact that they do not relate strictly to historical or current facts. These statements often may include words such as “anticipate,” “estimate,” “expect,” “project,” “plan,” “intend,” “believe,” “may,” “will,” “should,” “can have,” “likely” and other words and terms of similar meaning. These statements are based upon management’s current expectations, assumptions and estimates and are not guarantees of the timing or nature of our future operating or financial performance or other events. All forward-looking statements are subject to risks, uncertainties and other factors that may cause our actual results to differ materially from those that we expected, including:
The extent and duration of our revenue associated with COVID-19 related products and services are uncertain and are dependent, in important respects, on factors outside of our control.
We are dependent on the level of our customers’ spending on and demand for outsourced nucleic acid production and biologics safety testing products and services. A reduction in spending or change in spending priorities of our customers could significantly reduce demand for our products and services and could have a material adverse effect on our business, financial condition, results of operations, cash flows and prospects.
Ongoing macroeconomic challenges and changes in economic conditions, including adverse developments affecting banks and financial institutions, follow-on effects of those events and related systemic pressures, could negatively impact, directly or indirectly, our and our customers’ current and future business operations and our financial condition, revenue and earnings.
Certain of our products are used by customers in the production of vaccines and therapies, some of which represent relatively new and still-developing modes of treatment. Unforeseen adverse events, negative clinical outcomes, development of alternative therapies, or increased regulatory scrutiny of these and their financial cost may damage public perception of the safety, utility, or efficacy of these vaccines and therapies or other modes of treatment and may harm our customers’ ability to conduct their business. Such events may negatively impact our revenue and have an adverse effect on our performance.
We compete with life science, pharmaceutical and biotechnology companies who are substantially larger than we are and potentially capable of developing new approaches that could make our products, services and technology obsolete.
If our products and services do not perform as expected or the reliability of the technology on which our products and services are based is questioned, we could experience lost revenue, delayed or reduced market acceptance of our products and services, increased costs and damage to our reputation.
Our products are highly complex and are subject to quality control requirements.
Our commercial success depends on the market acceptance of our life science reagents. Our reagents may not achieve or maintain significant commercial market acceptance.
Our operating results may fluctuate significantly in the future, which makes our future operating results difficult to predict and could cause our operating results to fall below expectations or any guidance we may provide.
Ongoing geopolitical instability and the resulting economic disruption may negatively impact our business, operations and financial condition.
Our acquisitions expose us to risks that could adversely affect our business, and we may not achieve the anticipated benefits of acquisitions of businesses or technologies.
Product liability lawsuits against us could cause us to incur substantial liabilities, limit sales of our existing products and limit commercialization of any products that we may develop.
Our acquisitions expose us to risks that could adversely affect our business, and we may not achieve the anticipated benefits of acquisitions of businesses or technologies.
We depend on a limited number of customers for a high percentage of our revenue. If we cannot maintain our current relationships with customers, fail to sustain recurring sources of revenue with our existing customers, or if we fail to enter into new relationships, our future operating results will be adversely affected.
3


Table of Contents
We rely on a limited number of suppliers or, in some cases, sole suppliers, for some of our raw materials and may not be able to find replacements or immediately transition to alternative suppliers.
Our products could become subject to more onerous regulation by the FDA or other regulatory agencies in the future, which could increase our costs and delay or prevent commercialization of our products, thereby materially and adversely affecting our business, financial condition, results of operations, cash flows and prospects.
If we are unable to obtain, maintain and enforce intellectual property protection for our current or future products, or if the scope of our intellectual property protection is not sufficiently broad, our ability to commercialize our products successfully and to compete effectively may be materially adversely affected.
If we fail to comply with our obligations under any license agreements, disagree over contract interpretation, or otherwise experience disruptions to our business relationships with our licensors, we could lose intellectual property rights that are necessary to our business.
Our existing indebtedness could adversely affect our business and growth prospects.
Our principal asset is our interest in Maravai Topco Holdings, LLC (“Topco LLC”), and, accordingly, we depend on distributions from Topco LLC to pay our taxes and expenses, including payments under a tax receivable agreement with the former owners of Topco LLC (the “Tax Receivable Agreement” or “TRA”). Topco LLC’s ability to make such distributions may be subject to various limitations and restrictions.
Conflicts of interest could arise between our shareholders and Maravai Life Sciences Holdings, LLC (“MLSH 1”), the only other member of Topco LLC, which may impede business decisions that could benefit our shareholders.
The Tax Receivable Agreement requires us to make cash payments to MLSH 1 and Maravai Life Sciences Holdings 2, LLC (“MLSH 2”), an entity through which certain of our former owners hold their interests in the Company, in respect of certain tax benefits to which we may become entitled, and we expect that the payments we will be required to make will be substantial.
Our organizational structure, including the Tax Receivable Agreement, confers certain benefits upon MLSH 1 and MLSH 2 that will not benefit the other common shareholders to the same extent as they will benefit MLSH 1 and MLSH 2.
GTCR, LLC (“GTCR”) controls us, and its interests may conflict with ours or yours in the future.
Provisions of our corporate governance documents could make an acquisition of us more difficult and may prevent attempts by our shareholders to replace or remove our current management, even if beneficial to our shareholders.
We derive many of our forward-looking statements from our operating budgets and forecasts, which are based on many detailed assumptions. While we believe that our assumptions are reasonable, we caution that it is very difficult to predict the impact of known factors, and it is impossible for us to anticipate all factors that could affect our actual results. Important factors that could cause our actual results to differ materially from our expectations or cautionary statements are disclosed under the sections entitled “Risk Factors” and “Management’s Discussion and Analysis of Financial Condition and Results of Operations” in our Annual Report on Form 10-K for the year ended December 31, 2022 and in this Quarterly Report on Form 10-Q.
The forward-looking statements included in this report are made only as of the date hereof. We undertake no obligation to update or revise any forward-looking statement as a result of new information, future events or otherwise, except as otherwise required by law.

4


Table of Contents
Part I.
Item 1. Financial Statements and Supplementary Data
MARAVAI LIFESCIENCES HOLDINGS, INC.

CONDENSED CONSOLIDATED BALANCE SHEETS
(in thousands, except par value)
(Unaudited)
September 30, 2023December 31, 2022
Assets
Current assets:
Cash and cash equivalents$579,605 $632,138 
Accounts receivable, net45,674 138,624 
Inventory49,142 43,152 
Prepaid expenses and other current assets22,916 25,798 
Government funding receivable3,528 8,190 
Total current assets700,865 847,902 
Property and equipment, net153,565 52,694 
Goodwill326,029 283,668 
Intangible assets, net227,856 216,663 
Deferred tax assets773,659 765,799 
Other assets85,579 115,589 
Total assets$2,267,553 $2,282,315 
Liabilities and stockholders’ equity
Current liabilities:
Accounts payable$9,424 $5,991 
Accrued expenses and other current liabilities56,042 53,371 
Deferred revenue2,553 3,088 
Current portion of payable to related parties pursuant to the Tax Receivable Agreement4,198 42,254 
Current portion of long-term debt5,440 5,440 
Current portion of finance lease liabilities596  
Total current liabilities78,253 110,144 
Long-term debt, less current portion519,520 521,997 
Finance lease liabilities, less current portion32,077  
Deferred tax liabilities6,690  
Payable to related parties pursuant to the Tax Receivable Agreement, less current portion674,201 675,956 
Other long-term liabilities64,531 68,975 
Total liabilities1,375,272 1,377,072 
Stockholders’ equity:
Class A common stock, $0.01 par value - 500,000 shares authorized; 131,945 and 131,692 shares issued and outstanding as of September 30, 2023 and December 31, 2022, respectively
1,319 1,317 
Class B common stock, $0.01 par value - 300,000 shares authorized; 119,094 and 123,669 shares issued and outstanding as of September 30, 2023 and December 31, 2022, respectively
1,191 1,237 
Additional paid-in capital125,088 137,898 
Retained earnings391,696 404,766 
Total stockholders’ equity attributable to Maravai LifeSciences Holdings, Inc.519,294 545,218 
Non-controlling interest372,987 360,025 
Total stockholders’ equity892,281 905,243 
Total liabilities and stockholders’ equity$2,267,553 $2,282,315 
The accompanying notes are an integral part of these condensed consolidated financial statements.
5

Table of Contents
MARAVAI LIFESCIENCES HOLDINGS, INC.

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS
(in thousands, except per share amounts)
(Unaudited)

Three Months Ended
September 30,
Nine Months Ended
September 30,
2023202220232022
Revenue$66,865 $191,263 $214,804 $678,288 
Operating expenses:
Cost of revenue36,686 38,176 113,635 115,704 
Selling, general and administrative38,864 30,795 112,912 92,056 
Research and development4,347 5,389 12,686 13,358 
Change in estimated fair value of contingent consideration2,385  69 (7,800)
Total operating expenses82,282 74,360 239,302 213,318 
(Loss) income from operations(15,417)116,903 (24,498)464,970 
Other income (expense):
Interest expense(11,637)(3,136)(30,492)(10,234)
Interest income7,432  20,268  
Loss on extinguishment of debt   (208)
Change in payable to related parties pursuant to the Tax Receivable Agreement(1,007) (2,342)2,340 
Other income (expense)
66 (4)(1,386)(1,272)
(Loss) income before income taxes(20,563)113,763 (38,450)455,596 
Income tax (benefit) expense(5,461)14,110 (10,057)52,362 
Net (loss) income(15,102)99,653 (28,393)403,234 
Net (loss) income attributable to non-controlling interests(8,640)55,184 (15,323)220,663 
Net (loss) income attributable to Maravai LifeSciences Holdings, Inc.$(6,462)$44,469 $(13,070)$182,571 
Net (loss) income per Class A common share attributable to Maravai LifeSciences Holdings, Inc.:
Basic$(0.05)$0.34 $(0.10)$1.39 
Diluted$(0.05)$0.34 $(0.10)$1.37 
Weighted average number of Class A common shares outstanding:
Basic131,930 131,540 131,845 131,518 
Diluted131,930 131,651 131,845 255,323 
The accompanying notes are an integral part of these condensed consolidated financial statements.
6

Table of Contents
MARAVAI LIFESCIENCES HOLDINGS, INC.

CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE (LOSS) INCOME
(in thousands)
(Unaudited)

Three Months Ended
September 30,
Nine Months Ended
September 30,
2023202220232022
Net (loss) income$(15,102)$99,653 $(28,393)$403,234 
Comprehensive (loss) income attributable to non-controlling interests(8,640)55,184 (15,323)220,663 
Total comprehensive (loss) income attributable to Maravai LifeSciences Holdings, Inc.$(6,462)$44,469 $(13,070)$182,571 
The accompanying notes are an integral part of the condensed consolidated financial statements.
7

Table of Contents
MARAVAI LIFESCIENCES HOLDINGS, INC.

CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS’ EQUITY
(in thousands)
(Unaudited)

Three Months Ended September 30, 2023
Class A Common StockClass B Common Stock
SharesAmountSharesAmountAdditional Paid-In CapitalRetained EarningsNon-Controlling InterestTotal Stockholders’ Equity
June 30, 2023131,901$1,319 119,094$1,191 $119,903 $398,158 $377,067 $897,638 
Issuance of Class A common stock under employee equity plans, net of shares withheld for employee taxes44 — — — (242)— — (242)
Non-controlling interest adjustment for changes in proportionate ownership in Topco LLC— — — — 178 — (178) 
Stock-based compensation— — — — 5,249 — 4,738 9,987 
Net loss— — — — — (6,462)(8,640)(15,102)
September 30, 2023131,945$1,319 119,094$1,191 $125,088 $391,696 $372,987 $892,281 

Nine Months Ended September 30, 2023
Class A Common StockClass B Common Stock
SharesAmountSharesAmountAdditional Paid-In CapitalRetained EarningsNon-Controlling InterestTotal Stockholders’ Equity
December 31, 2022131,692$1,317 123,669$1,237 $137,898 $404,766 $360,025 $905,243 
Effects of Structuring Transactions
— — (4,575)(46)(26,348)— 26,392 (2)
Issuance of Class A common stock under employee equity plans, net of shares withheld for employee taxes253 2 — — (208)— — (206)
Non-controlling interest adjustment for changes in proportionate ownership in Topco LLC— — — — 493 — (493) 
Stock-based compensation— — — — 13,253 — 11,993 25,246 
Distribution for tax liabilities to non-controlling interest holder— — — — — — (9,607)(9,607)
Net loss— — — — — (13,070)(15,323)(28,393)
September 30, 2023131,945$1,319 119,094$1,191 $125,088 $391,696 $372,987 $892,281 

8

Table of Contents
Three Months Ended September 30, 2022
Class A Common StockClass B Common Stock
SharesAmountSharesAmountAdditional Paid-In CapitalRetained EarningsNon-Controlling InterestTotal Stockholders’ Equity
June 30, 2022131,539$1,315 123,669$1,237 $131,373 $322,663 $317,204 $773,792 
Effect of exchange of LLC Units
— — — — — — —  
Issuance of Class A common stock under employee equity plans, net of shares withheld for employee taxes1 — — — 25 — — 25 
Non-controlling interest adjustment for changes in proportionate ownership in Topco LLC— — — — (35)— 35  
Stock-based compensation— — — — 2,443 — 2,297 4,740 
Distribution for tax liabilities to non-controlling interest holder— — — — 271 — (36,812)(36,541)
Net income— — — — — 44,469 55,184 99,653 
September 30, 2022131,540$1,315 123,669$1,237 $134,077 $367,132 $337,908 $841,669 

Nine Months Ended September 30, 2022
Class A Common StockClass B Common Stock
SharesAmountSharesAmountAdditional Paid-In CapitalRetained EarningsNon-Controlling InterestTotal Stockholders’ Equity
December 31, 2021131,488$1,315 123,669$1,237 $128,386 $184,561 $229,862 $545,361 
Issuance of Class A common stock under employee equity plans, net of shares withheld for employee taxes52 — — — 1,173 — — 1,173 
Non-controlling interest adjustment for changes in proportionate ownership in Topco LLC— — — — (529)— 529  
Stock-based compensation— — — — 6,532 — 6,143 12,675 
Distribution for tax liabilities to non-controlling interest holder— — — — 206 — (119,289)(119,083)
Impact of change to deferred tax asset associated with cash contribution to Topco LLC
— — — — (1,691)— — (1,691)
Net income— — — — — 182,571 220,663 403,234 
September 30, 2022131,540$1,315 123,669$1,237 $134,077 $367,132 $337,908 $841,669 
The accompanying notes are an integral part of the condensed consolidated financial statements.
9

Table of Contents
MARAVAI LIFESCIENCES HOLDINGS, INC.

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS
(in thousands)
(Unaudited)

Nine Months Ended
September 30,
20232022
Operating activities:
Net (loss) income$(28,393)$403,234 
Adjustments to reconcile net (loss) income to net cash provided by operating activities:
Depreciation8,966 5,604 
Amortization of intangible assets20,487 18,033 
Amortization of operating lease right-of-use assets6,348 4,437 
Amortization of deferred financing costs2,186 2,134 
Stock-based compensation expense25,246 12,675 
Loss on extinguishment of debt 208 
Deferred income taxes(9,808)35,307 
Change in estimated fair value of contingent consideration69 (7,800)
Revaluation of liabilities under the Tax Receivable Agreement2,342 (2,340)
Other(4,474)(5,529)
Changes in operating assets and liabilities:
Accounts receivable93,180 3,502 
Inventory2,833 (9,814)
Prepaid expenses and other assets1,761 (36,375)
Accounts payable3,625 1,890 
Accrued expenses and other current liabilities8,962 14,114 
Deferred revenue(558)(4,388)
Other long-term liabilities(14,338)1,750 
Net cash provided by operating activities118,434 436,642 
Investing activities:
Cash paid for acquisition of a business, net of cash acquired(69,622)(238,836)
Purchases of property and equipment(48,754)(10,876)
Proceeds from government assistance allocated to property and equipment8,969  
Proceeds from sale of business, net of cash divested 620 
Net cash used in investing activities(109,407)(249,092)
Financing activities:
Distributions for tax liabilities to non-controlling interest holders(9,607)(119,289)
Proceeds from borrowings of long-term debt 8,455 
Principal repayments of long-term debt(4,080)(12,535)
Payments of finance lease liabilities(190) 
Proceeds from derivative instruments3,845  
Payment of acquisition consideration holdback(9,706) 
Payments to MLSH 1 pursuant to the Tax Receivable Agreement(35,661) 
Payments to MLSH 2 pursuant to the Tax Receivable Agreement(6,492) 
Proceeds from issuance of Class A common stock under employee equity plans, net of shares withheld for employee taxes
331 1,993 
Net cash used in financing activities(61,560)(121,376)
Net (decrease) increase in cash and cash equivalents
(52,533)66,174 
Cash and cash equivalents, beginning of period632,138 551,272 
10

Table of Contents
Nine Months Ended
September 30,
20232022
Cash and cash equivalents, end of period$579,605 $617,446 
Supplemental cash flow information:
Cash paid for interest$32,188 $11,416 
Cash (refunded) paid for income taxes, net$(3,077)$19,581 
Supplemental disclosures of non-cash activities:
Property and equipment included in accounts payable and accrued expenses$3,703 $1,799 
Accrued receivable for capital expenditures to be reimbursed under a government contract$3,528 $1,105 
Right-of-use assets obtained in exchange for new finance lease liabilities$32,862 $ 
Right-of-use assets obtained in exchange for new operating lease liabilities$3,931 $7,872 
Fair value of contingent consideration liability recorded in connection with acquisition of a business$5,289 $7,800 
Accrued consideration payable for MyChem acquisition
$ $10,000 
The accompanying notes are an integral part of the condensed consolidated financial statements.
11

Table of Contents
MARAVAI LIFESCIENCES HOLDINGS, INC.

NOTES TO THE CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
1.Organization and Significant Accounting Policies
Description of Business
Maravai LifeSciences Holdings, Inc. (the “Company”, and together with its consolidated subsidiaries, “Maravai”, “we”, “us”, and “our”) provides critical products to enable the development of drugs, therapeutics, diagnostics and vaccines and to support research on human diseases. Our products address the key phases of biopharmaceutical development and include complex nucleic acids for diagnostic and therapeutic applications and antibody-based products to detect impurities during the production of biopharmaceutical products.
The Company is headquartered in San Diego, California, and has two principal businesses: Nucleic Acid Production and Biologics Safety Testing. Our Nucleic Acid Production business manufactures and sells products used in the fields of gene therapy, vaccines, nucleoside chemistry, oligonucleotide therapy and molecular diagnostics, including reagents used in the chemical synthesis, modification, labelling and purification of deoxyribonucleic acid (“DNA”) and ribonucleic acid (“RNA”). Our core Nucleic Acid Production offerings include messenger ribonucleic acid (“mRNA”), long and short oligonucleotides, our proprietary CleanCap® capping technology and oligonucleotide building blocks, and custom enzyme development and manufacturing. Our Biologics Safety Testing business sells highly specialized analytical products for use in biologic manufacturing process development, including custom product-specific development antibody and assay development services.
Organization and Organizational Transactions
We were incorporated as a Delaware corporation in August 2020 for the purpose of facilitating an initial public offering (“IPO”). Immediately prior to the IPO, we effected a series of organizational transactions (the “Organizational Transactions”), which, together with the IPO, were completed in November 2020, that resulted in the Company operating, controlling all of the business affairs and becoming the ultimate parent company of Maravai Topco Holdings, LLC (“Topco LLC”) and its consolidated subsidiaries. Maravai Life Sciences Holdings, LLC (“MLSH 1”), which is controlled by investment entities affiliated with GTCR, is the only other member of Topco LLC.
The Company is the sole managing member of Topco LLC, which operates and controls TriLink Biotechnologies, LLC (“TriLink”), Glen Research, LLC, MockV Solutions, LLC, Cygnus Technologies, LLC (“Cygnus”) and Alphazyme, LLC (“Alphazyme”) and their respective subsidiaries.
In connection with the Company’s acquisition of Alphazyme (see Note 2), the Company undertook a series of structuring transactions (the “Structuring Transactions”), including:
On January 18, 2023, the Company acquired all of the outstanding membership interests in Alphazyme (see Note 2).
On January 19, 2023, the Company entered into a contribution agreement (the “Contribution Agreement”) with Alphazyme Holdings, Inc. (“Alphazyme Holdings”), a wholly owned subsidiary of the Company, pursuant to which the Company contributed all such membership interests in Alphazyme (the “Alphazyme Membership Interest”) to Alphazyme Holdings.
On January 22, 2023, Alphazyme Holdings entered into a contribution and exchange agreement (the “Contribution and Exchange Agreement”) with Topco LLC, pursuant to which it contributed all of the Alphazyme Membership Interests to TopCo LLC in exchange for 5,059,134 newly-issued LLC Units of Topco LLC at a price per unit of $13.87, which was equal to the 50-day volume-weighted average price of the Company’s Class A common stock as calculated on January 18, 2023 (the “Contribution and Exchange”).
Immediately following the Contribution and Exchange, the Company entered into a forfeiture agreement (the “Forfeiture Agreement”) with Alphazyme Holdings, TopCo LLC and MLSH 1, a related party, pursuant to which each of the Company (together with Alphazyme Holdings) and MLSH 1 agreed to forfeit 5,059,134 and 4,871,970 LLC Units, respectively, representing 3.7% of the Company’s (together with Alphazyme Holdings) and MLSH 1’s respective LLC Units of Topco LLC, and an equal number of shares of the Company’s Class B common stock, par value $0.01 per share, were forfeited by MLSH 1, in each case for no consideration.
These were considered transactions between entities under common control. As a result, the consolidated financial statements for periods prior to the these transactions have been adjusted to combine the previously separate entities for presentation purposes.
12

Table of Contents
Basis of Presentation
The Company operates and controls all of the business and affairs of Topco LLC, and, through Topco LLC and its subsidiaries, conducts its business. Because we manage and operate the business and control the strategic decisions and day-to-day operations of Topco LLC and also have a substantial financial interest in Topco LLC, we consolidate the financial results of Topco LLC, and a portion of our net (loss) income is allocated to the non-controlling interests in Topco LLC held by MLSH 1.
The accompanying unaudited interim condensed consolidated financial statements include the accounts of the Company and its subsidiaries. All intercompany transactions and accounts between the businesses comprising the Company have been eliminated in the accompanying consolidated financial statements.
Unaudited Interim Condensed Consolidated Financial Statements
The accompanying unaudited condensed consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America (“GAAP”) for interim financial information and pursuant to Form 10-Q of Regulation S-X of the Securities and Exchange Commission (“SEC”). Accordingly, they do not include all of the information and footnotes required by GAAP for complete financial statements. These unaudited condensed consolidated financial statements include all adjustments necessary to fairly state the financial position and the results of our operations and cash flows for interim periods in accordance with GAAP. All such adjustments are of a normal, recurring nature. Operating results for the three and nine months ended September 30, 2023 are not necessarily indicative of the results that may be expected for the year ending December 31, 2023 or for any future period.
The condensed consolidated balance sheet presented as of December 31, 2022 has been derived from the audited consolidated financial statements as of that date. The condensed consolidated financial statements and notes are presented as permitted by Form 10-Q and do not contain all information that is included in the annual financial statements and notes thereto of the Company. The condensed consolidated financial statements and notes included in this report should be read in conjunction with the consolidated financial statements and notes included in the Company’s Annual Report on Form 10-K for the year ended December 31, 2022 (“2022 Form 10-K”) filed with the SEC.
Use of Estimates
The preparation of consolidated financial statements in accordance with GAAP requires the Company to make judgments, estimates and assumptions that affect the reported amounts of assets, liabilities, equity, revenue and expenses, and related disclosures. These estimates form the basis for judgments the Company makes about the carrying values of assets and liabilities that are not readily apparent from other sources. The Company bases its estimates and judgments on historical experience and on various other assumptions that the Company believes are reasonable under the circumstances. These estimates are based on management’s knowledge about current events and expectations about actions the Company may undertake in the future. Significant estimates include, but are not limited to, the measurement of right-of-use assets and lease liabilities and related incremental borrowing rate, the payable to related parties pursuant to the Tax Receivable Agreement (as defined in Note 12), the realizability of our net deferred tax assets, and the valuation of goodwill and intangible assets acquired in business combinations. Actual results could differ materially from those estimates.
Significant Accounting Policies
A description of the Company’s significant accounting policies is included in Note 1 of the Notes to the Consolidated Financial Statements included in its 2022 Form 10-K. There have been no material changes in the Company’s significant accounting policies during the three and nine months ended September 30, 2023.
Revenue Recognition
The Company generates revenue primarily from the sale of products and, to a much lesser extent, services in the fields of nucleic acid production and biologics safety testing. Revenue is recognized when control of promised goods or services is transferred to a customer in an amount that reflects the consideration to which the entity expects to be entitled in exchange for those goods or services. To determine revenue recognition for its arrangements with customers, the Company performs the following five steps: (i) identify the contract(s) with a customer; (ii) identify the performance obligations in the contract; (iii) determine the transaction price; (iv) allocate the transaction price to the performance obligations in the contract; and (v) recognize revenue when (or as) the entity satisfies a performance obligation. The majority of the Company’s contracts include only one performance obligation. A performance obligation is a promise in a contract to transfer a distinct good or service to the customer and is defined as the unit of account for revenue recognition. The Company also recognizes revenue from other contracts that may include a combination of products and services, the provision of solely services, or from license fee arrangements which may be associated with the delivery of product. Where there is a combination of products and services, the Company accounts for the promises as individual performance obligations if they are concluded to be distinct. Performance
13

Table of Contents
obligations are considered distinct if they are both capable of being distinct and distinct within the context of the contract. In determining whether performance obligations meet the criteria for being distinct, the Company considers a number of factors, such as the degree of interrelation and interdependence between obligations, and whether or not the good or service significantly modifies or transforms another good or service in the contract. As a practical expedient, we do not adjust the transaction price for the effects of a significant financing component if, at contract inception, the period between customer payment and the transfer of goods or services is expected to be one year or less. Contracts with customers are evaluated on a contract-by-contract basis as contracts may include multiple types of goods and services as described below.
Nucleic Acid Production
Nucleic Acid Production revenue is generated from the manufacture and sale of highly modified, complex nucleic acids products to support the needs of our customers’ research, therapeutic and vaccine programs. The primary offering of products includes CleanCap®, mRNA and specialized oligonucleotides. Contracts typically consist of a single performance obligation. We also sell nucleic acid products for labeling and detecting proteins in cells and tissue samples research. The Company recognizes revenue from these products in the period in which the performance obligation is satisfied by transferring control to the customer. Revenue for nucleic acid catalog products is recognized at a single point in time, generally upon shipment to the customer. Revenue for contracts for certain custom nucleic acid products, with an enforceable right to payment and a reasonable margin for work performed to date, is recognized over time, based on a cost-to-cost input method over the manufacturing period. Payments received from customers in advance of manufacturing their products is recorded as deferred revenue until the products are delivered.
Biologics Safety Testing
The Company’s Biologics Safety Testing revenue is associated with the sale of bioprocess impurity detection kit products. We also enter into contracts that include custom antibody development, assay development and antibody affinity extraction services. These products and services enable the detection of impurities that occur in the manufacturing of biologic drugs and other therapeutics. The Company recognizes revenue from the sale of bioprocess impurity detection kits in the period in which the performance obligation is satisfied by transferring control to the customer. Custom antibody development contracts consist of a single performance obligation, typically with an enforceable right to payment and a reasonable margin for work performed to date. Revenue is recognized over time based on a cost-to-cost input method over the contract term. Where an enforceable right to payment does not exist, revenue is recognized at a point in time when control is transferred to the customer. Assay development service contracts consist of a single performance obligation. Revenue is recognized at a point in time when a successful antigen test and report is provided to the customer. Affinity extraction services, which generally occur over a short period of time, consist of a single performance obligation to perform the extraction service and provide a summary report to the customer. Revenue is recognized either over time or at a point in time depending on contractual payment terms with the customer.
The Company elected the practical expedient to not disclose the unfulfilled performance obligations for contracts with an original length of one year or less. The Company had no material unfulfilled performance obligations for contracts with an original length greater than one year for any period presented.
The Company accepts returns only if the products do not meet customer specifications, and historically, the Company’s volume of product returns has not been significant. Further, no warranties are provided for promised goods and services other than assurance type warranties.
Revenue for an individual contract is recognized at the related transaction price, which is the amount the Company expects to be entitled to in exchange for transferring the products and/or services. The transaction price for product sales is calculated at the contracted product selling price. The transaction price for a contract with multiple performance obligations is allocated to the separate performance obligations on a relative standalone selling price basis. Standalone selling prices for products are determined based on the prices charged to customers, which are directly observable. Standalone selling price of services are mostly based on time and materials. Generally, payments from customers are due when goods and services are transferred. As most contracts contain a single performance obligation, the transaction price is representative of the standalone selling price charged to customers. Revenue is recognized only to the extent that it is probable that a significant reversal of the cumulative amount recognized will not occur in future periods. Variable consideration has not been material to our consolidated financial statements.
Sales taxes
Sales taxes collected by the Company are not included in the transaction price as revenue as they are ultimately remitted to a governmental authority.
14

Table of Contents
Shipping and handling costs
The Company has elected to account for shipping and handling activities related to contracts with customers as costs to fulfill the promise to transfer the associated products. Accordingly, revenue for shipping and handling is recognized at the same time that the related product revenue is recognized.
Contract costs
The Company recognizes the incremental costs of obtaining contracts as an expense when incurred when the amortization period of the assets that otherwise would have been recognized is one year or less. These costs are included in sales and marketing and general and administrative expenses. The costs to fulfill the contracts are determined to be immaterial and are recognized as an expense when incurred.
Contract balances
Contract assets are generated when contractual billing schedules differ from revenue recognition timing and the Company records a contract receivable when it has an unconditional right to consideration. There were no contract asset balances as of September 30, 2023 and December 31, 2022.
Contract liabilities include billings in excess of revenue recognized, such as customer deposits and deferred revenue. Customer deposits, which are included in accrued expenses, are recorded when cash payments are received or due in advance of performance. Deferred revenue is recorded when the Company has unsatisfied performance obligations. Total contract liabilities was $4.8 million as of September 30, 2023 and December 31, 2022. Contract liabilities are expected to be recognized as revenue within the next twelve months.
Disaggregation of revenue
The following tables summarize the revenue by segment and region for the periods presented (in thousands):
Three Months Ended September 30, 2023
Nucleic Acid ProductionBiologics Safety TestingTotal
North America$27,893$6,622$34,515
Europe, the Middle East and Africa3,7033,9197,622
Asia Pacific19,6015,02224,623
Latin and Central America3174105
Total revenue$51,228$15,637$66,865
Nine Months Ended September 30, 2023
Nucleic Acid ProductionBiologics Safety TestingTotal
North America$88,961$20,392$109,353
Europe, the Middle East and Africa21,34512,41833,763
Asia Pacific55,49515,82071,315
Latin and Central America143230373
Total revenue$165,944$48,860$214,804
Three Months Ended September 30, 2022
Nucleic Acid ProductionBiologics Safety TestingTotal
North America$91,130$6,583$97,713
Europe, the Middle East and Africa77,7554,06981,824
Asia Pacific5,9315,54111,472
Latin and Central America65189254
Total revenue$174,881$16,382$191,263
15

Table of Contents
Nine Months Ended September 30, 2022
Nucleic Acid ProductionBiologics Safety TestingTotal
North America$252,563$21,274$273,837
Europe, the Middle East and Africa322,56613,344335,910
Asia Pacific48,53519,47468,009
Latin and Central America115417532
Total revenue$623,779$54,509$678,288
Total revenue is attributed to geographic regions based on the bill-to location of the transaction. For all periods presented, the majority of our revenue was recognized at a point in time.
Non-Controlling Interests
Non-controlling interests represent the portion of profit or loss, net assets and comprehensive (loss) income of our consolidated subsidiaries that is not allocable to the Company based on our percentage of ownership of such entities.
In November 2020, following the completion of the Organizational Transactions, we became the sole managing member of Topco LLC. As of September 30, 2023, we held approximately 52.6% of the outstanding LLC Units of Topco LLC, and MLSH 1 held approximately 47.4% of the outstanding LLC Units of Topco LLC. Therefore, we report non-controlling interests based on the percentage of LLC Units of Topco LLC held by MLSH 1 on the condensed consolidated balance sheet as of September 30, 2023. Income or loss attributed to the non-controlling interest in Topco LLC is based on the LLC Units outstanding during the period for which the income or loss is generated and is presented on the condensed consolidated statements of operations and condensed consolidated statements of comprehensive (loss) income.
MLSH 1 is entitled to exchange its LLC Units of Topco LLC, together with an equal number of shares of our Class B common stock (together referred to as “Paired Interests”), for shares of Class A common stock on a one-for-one basis or, at our election, for cash, from a substantially concurrent public offering or private sale (based on the price of our Class A common stock in such public offering or private sale). As such, future exchanges of Paired Interests by MLSH 1 will result in a change in ownership and reduce or increase the amount recorded as non-controlling interests and increase or decrease additional paid-in-capital when Topco LLC has positive or negative net assets, respectively. For the nine months ended September 30, 2023 and 2022, MLSH 1 did not exchange any Paired Interests.
Distributions of $9.6 million for tax liabilities were made to MLSH 1 during the nine months ended September 30, 2023. Distributions of $36.8 million and $119.3 million for tax liabilities were made to MLSH 1 during the three and nine months ended September 30, 2022, respectively. No such distributions were made during the three months ended September 30, 2023.
Segment Information
The Company operates in two reportable segments. Operating segments are defined as components of an enterprise for which separate financial information is evaluated regularly by the Company’s chief operating decision maker (“CODM”) in deciding how to allocate resources and assessing performance. The CODM allocates resources and assesses performance based upon discrete financial information at the segment level. All of our long-lived assets are located in the United States.
Cash and Cash Equivalents
The Company considers all highly liquid investments with original maturities of three months or less to be cash equivalents. The carrying value of these cash equivalents approximates fair value. Cash and cash equivalents consist of deposits held at financial institutions and money market funds.
Accounts Receivable and Allowance for Credit Losses
Accounts receivable primarily consist of amounts due from customers for product sales and services. The Company’s expected credit losses are developed using an estimated loss rate method that considers historical collection experience, current conditions, and reasonable and supportable forecasts that affect the collectability of the reported amount. The estimated loss rates are applied to trade receivables with similar risk characteristics such as the length of time the balance has been outstanding, liquidity and financial position of the customer, and the geographic location of the customer. In certain instances, the Company may identify individual accounts receivable assets that do not share risk characteristics with other accounts receivable, in which case the Company records its expected credit losses on an individual asset basis.
16

Table of Contents
The allowance for credit losses was approximately $2.2 million as of September 30, 2023 and December 31, 2022. Write-offs of accounts receivable were not significant during the three and nine months ended September 30, 2023. There were $0.5 million of recoveries during the nine months ended September 30, 2023. There were no recoveries during the three months ended September 30, 2023. Write-offs of accounts receivable and recoveries were not significant during the three and nine months ended September 30, 2022.
Net (Loss) Income per Class A Common Share Attributable to Maravai LifeSciences Holdings, Inc.
Basic net (loss) income per Class A common share attributable to Maravai LifeSciences Holdings, Inc. is computed by dividing net (loss) income attributable to us by the weighted average number of Class A common shares outstanding during the period. Diluted net (loss) income per Class A common share is calculated by giving effect to all potential weighted average dilutive stock options, restricted stock units, and Topco LLC Units, that together with an equal number of shares of our Class B common stock, are convertible into shares of our Class A common stock. The dilutive effect of outstanding awards, if any, is reflected in diluted earnings per share by application of the treasury stock method or if-converted method, as applicable. The Company reported net (loss) income attributable to Maravai LifeSciences Holdings, Inc. for the three and nine months ended September 30, 2023 and 2022.
Government Assistance
The consideration awarded to the Company by the U.S. Department of Defense is outside the scope of the contracts with customers, income tax, funded research and development, and contribution guidance. This is because the awarding entity is not considered to be a customer, the receipt of the funding is not predicated on the Company’s income tax position, there are no refund provisions, and the entity is not receiving reciprocal value for their support provided to the Company. The Company’s elected policy is to recognize such assistance as a reduction to the carrying amount of the assets associated with the award when it is reasonably assured that the funding will be received as evidenced through the existence of an arrangement, amounts eligible for reimbursement are determinable and have been incurred or paid, the applicable conditions under the arrangement have been met, and collectability of amounts due is reasonably assured.
Fair Value of Financial Instruments
The Company defines fair value as the amount that would be received to sell an asset, or paid to transfer a liability, in an orderly transaction between market participants at the measurement date. The Company follows accounting guidance that has a three-level hierarchy for fair value measurements based upon the transparency of inputs to the valuation of the asset or liability as of the measurement date. Instruments with readily available actively quoted prices, or for which fair value can be measured from actively quoted prices in an orderly market, will generally have a higher degree of market price transparency and a lesser degree of judgment used in measuring fair value. The three levels of the hierarchy are defined as follows:
Level 1—Observable inputs that reflect quoted prices (unadjusted) for identical assets or liabilities in active markets;
Level 2—Include other inputs that are directly or indirectly observable in the marketplace; and
Level 3—Unobservable inputs which are supported by little or no market activity.
As of September 30, 2023 and December 31, 2022, the carrying value of the Company’s current assets and liabilities approximated fair value due to the short maturities of these instruments. The fair values of the Company’s long-term debt approximated carrying value, excluding the effect of unamortized debt discount, as it is based on borrowing rates currently available to the Company for debt with similar terms and maturities (Level 2 inputs).
Acquisitions
The Company evaluates mergers, acquisitions and other similar transactions to assess whether or not the transaction should be accounted for as a business combination or an acquisition of assets. The Company first identifies the acquiring entity by determining if the target is a legal entity or a group of assets or liabilities. If control over a legal entity is being evaluated, the Company also evaluates if the target is a variable interest or voting interest entity. For acquisitions of voting interest entities, the Company applies a screen test to determine if substantially all of the fair value of the gross assets acquired is concentrated in a single identifiable asset or group of similar identifiable assets. If the screen test is met, the transaction is accounted for as an acquisition of assets. If the screen is not met, further determination is required as to whether or not the Company has acquired inputs and processes that have the ability to create outputs which would meet the definition of a business.
The Company accounts for its business combinations using the acquisition method of accounting which requires that the assets acquired and liabilities assumed of acquired businesses be recorded at their respective fair values at the date of acquisition. The purchase price, which includes the fair value of consideration transferred, is attributed to the fair value of the assets acquired
17

Table of Contents
and liabilities assumed. The purchase price may also include contingent consideration. The Company assesses whether such contingent consideration is subject to liability classification and fair value measurement or meets the definition of a derivative. Contingent consideration liabilities are recognized at their estimated fair value on the acquisition date. Contingent consideration arrangements that are determined to be compensatory in nature are recognized as post combination expense in our condensed consolidated statements of operations ratably over the implied service period beginning in the period it becomes probable such amounts will become payable. The excess of the purchase price of the acquisition over the fair value of the identifiable net assets of the acquiree is recorded as goodwill. The fair value of assets acquired and liabilities assumed in certain cases may be subject to revision based on the final determination of fair value during a period of time not to exceed twelve months from the acquisition date. The results of acquired businesses are included in the Company’s consolidated financial statements from the date of acquisition. Transaction costs directly attributable to acquired businesses are expensed as incurred.
Determining the fair value of intangible assets acquired, defined as the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between willing market participants, requires management to use significant judgment, including the selection of valuation methodologies, assumptions about future net cash flows, and discount rates. Each of these factors can significantly affect the value attributed to the identifiable intangible asset acquired in a business combination.
Contingent Consideration
Contingent consideration represents additional consideration that may be transferred to former owners of an acquired entity in the future if certain future events occur or conditions are met. Contingent consideration resulting from the acquisition of a business is recorded at fair value on the acquisition date. Such contingent consideration is re-measured to its estimated fair value at each reporting date with the change in fair value recognized within operating expenses in the Company’s condensed consolidated statements of operations. Subsequent changes in the fair value of the contingent consideration are classified as an adjustment to cash flows from operating activities in the condensed consolidated statements of cash flows because the change in fair value is an input in determining net (loss) income. Cash paid in settlement of contingent consideration liabilities are classified as cash flows from financing activities up to the acquisition date fair value with any excess classified as cash flows from operating activities.
Changes in the fair value of contingent consideration liabilities associated with the acquisition of a business can result from updates to assumptions such as the expected timing or probability of achieving customer-related performance targets, specified sales milestones, changes in projected revenue or changes in discount rates. Judgment is used in determining those assumptions as of the acquisition date and for each subsequent reporting period. Therefore, any changes in the fair value will impact the Company’s results of operations in such reporting period, thereby resulting in potential variability in the Company’s operating results until such contingencies are resolved.
Concentration of Credit Risk
Financial instruments that potentially subject the Company to significant concentrations of credit risk consist principally of cash and accounts receivable. The Company maintains substantially all of its cash balances at a financial institution that management believes is of high credit-quality and is financially stable. Cash is deposited with major financial institutions in excess of Federal Deposit Insurance Corporation (“FDIC”) insurance limits. The Company believes it is not exposed to significant credit risk due to the financial strength of the depository institutions in which the cash is held. The Company provides credit, in the normal course of business, to international and domestic distributors and customers, which are geographically dispersed. The Company attempts to limit its credit risk by performing ongoing credit evaluations of its customers and maintaining adequate allowances for potential credit losses.
The following table summarizes revenue from each of our customers who individually accounted for 10% or more of our total revenue or accounts receivable for the periods presented:
RevenueAccounts Receivable, net
Three Months Ended
September 30,
Nine Months Ended
September 30,
September 30, 2023December 31, 2022
2023202220232022
Nacalai USA, Inc.22.9 %*18.5 %*32.9 %20.3 %
BioNTech SE*38.7 %*37.2 %*12.0 %
Pfizer Inc.*29.1 %*30.4 %*19.2 %
CureVac N.V.*****15.7 %
____________________
*Less than 10%
18

Table of Contents
For the three and nine months ended September 30, 2023, all of the revenue recorded for Nacalai USA, Inc. was generated by the Nucleic Acid Production Segment. For the three and nine months ended September 30, 2022, substantially all of the revenue recorded for BioNTech SE and Pfizer Inc. was generated by the Nucleic Acid Production segment.
2.Acquisitions
Alphazyme, LLC
On January 18, 2023, the Company completed the acquisition of Alphazyme, LLC (“Alphazyme”), a privately-held original equipment manufacturer (“OEM”) provider of custom, scalable, molecular biology enzymes to customers in the genetic analysis and nucleic acid synthesis markets. The acquisition will expand the Company’s internal enzyme product portfolio and increase the Company’s differentiated mRNA manufacturing services and product offerings. Alphazyme’s ability to manufacture custom enzymes allows the Company to expand into near adjacent markets and raise our enzyme vertical.
The Company acquired Alphazyme for a total purchase consideration of $75.3 million, subject to customary post-closing adjustments, including a working capital settlement. The total cash consideration was paid using existing cash on hand. The transaction was accounted for as an acquisition of a business as Alphazyme consisted of inputs and processes applied to those inputs that had the ability to contribute to the creation of outputs.
For the nine months ended September 30, 2023, the Company incurred $4.1 million in transaction costs associated with the acquisition of Alphazyme, which were recorded within selling, general and administrative expenses in the condensed consolidated statements of operations. The Company did not incur any such transaction costs during the three months ended September 30, 2023.
The acquisition date fair value of consideration transferred to acquire Alphazyme consisted of the following (in thousands):
Cash paid (1)
$70,037 
Fair value of contingent consideration5,289 
Total consideration transferred$75,326 
____________________
(1)Represents cash consideration paid at closing of $70.1 million, net of a purchase price adjustment received in June 2023 of $0.1 million.
Pursuant to the Securities Purchase Agreement (the “Alphazyme SPA”) between the Company and sellers of Alphazyme, additional payments to the sellers of Alphazyme are dependent upon meeting or exceeding defined revenue targets during fiscal years 2023 through 2025 (the “Alphazyme Performance Payments”). The Alphazyme SPA provides for a total maximum Alphazyme Performance Payments of $75.0 million. The Alphazyme Performance Payments were recorded as contingent consideration and was included as part of the purchase consideration. The Company estimated the fair value of the Alphazyme Performance Payments contingent consideration based on a Monte-Carlo simulation model which utilized an income approach. The estimated fair value was based on Alphazyme revenue projections, expected payout term, volatility and risk adjusted discount rates which are Level 3 inputs (see Note 4).
The Alphazyme SPA also provides that the Company will pay certain employees of Alphazyme an additional amount totaling $9.3 million (the “Alphazyme Retention Payments”) as of various dates but primarily through December 31, 2025 as long as these individuals continue to be employed by the Company. The Company considers the payment of the Alphazyme Retention Payments as probable and is recognizing compensation expense related to these payments in the post-acquisition period ratably over the service period of approximately three years. For the three and nine months ended September 30, 2023, the Company recorded $0.6 million and $1.6 million, respectively, of compensation expense related to the Alphazyme Retention Payments within selling, general and administrative expenses in the condensed consolidated statements of operations. Compensation expense related to the Alphazyme Retention Payments recorded within cost of revenue and research and development expenses were not material.
The Company is in the process of finalizing the evaluation of the income tax implications related to the Structuring Transactions (see Note 1), which may change the allocation of purchase consideration and provisional measurements of
19

Table of Contents
deferred tax liabilities and goodwill. The following table summarizes the estimated fair values of the assets acquired and liabilities assumed at the acquisition date (in thousands):
Cash$288 
Inventory7,246 
Other current assets660 
Intangible assets, net31,680 
Other assets5,043 
Total identifiable assets acquired44,917 
Current liabilities(482)
Other long-term liabilities(11,470)
Total liabilities assumed(11,952)
Net identifiable assets acquired32,965 
Goodwill42,361 
Net assets acquired$75,326 
We recorded the preliminary purchase price allocation in the first quarter of 2023. During the three months ended September 30, 2023, we recorded a measurement period adjustment resulting in a decrease to goodwill of $0.4 million, with an equal offset to other long-term liabilities.
The acquisition was accounted for under the acquisition method of accounting, and therefore, the total purchase price was allocated to the identifiable tangible and intangible assets acquired and the liabilities assumed based on their respective fair values as of the acquisition date. Purchase consideration in excess of the amounts recognized for the net assets acquired was recognized as goodwill. Goodwill is primarily attributable to expanded synergies expected from the acquisition associated with a vertical supply integration. All of the goodwill acquired in connection with the acquisition of Alphazyme was allocated to the Company’s Nucleic Acid Production segment. None of the goodwill recognized is expected to be deductible for income tax purposes.
Upon closing of the acquisition, approximately $1.5 million was placed into escrow to cover potential working capital adjustments and approximately $3.0 million was placed into escrow to secure certain representations and warranties pursuant to the terms of the Alphazyme SPA. These amounts are included in the total purchase consideration of $75.3 million. The $1.5 million was released from escrow during the second quarter of 2023, of which the Company received $0.1 million related to net working capital adjustments. Because the remaining $3.0 million held in escrow is not controlled by the Company, this amount is not included in the accompanying condensed consolidated balance sheet as of September 30, 2023.
The following table summarizes the estimated fair values of Alphazyme’s identifiable intangible assets as of the date of acquisition and their estimated useful lives:
Estimated Fair Value
(in thousands)
Estimated Useful Life
(in years)
Trade names$220 5
Developed technology31,000 12
Customer relationships460 12
Total$31,680 
The trade name and customer relationship intangible assets are related to Alphazyme’s name, customer loyalty and customer relationships. The developed technology intangible asset is related to its unique manufacturing process optimization capability to both scale production and achieve quality standards. The fair value of these intangible assets was based on Alphazyme’s projected revenues and was estimated using an income approach, specifically the relief from royalty method for trade names, the multi-period excess earnings method for developed technology, and the distributor method for customer relationships. Under the income approach, an intangible asset’s fair value is equal to the present value of future economic benefits to be derived from ownership of the asset. The estimated fair value was developed by discounting future net cash flows to their present value at market-based rates of return utilizing Level 3 inputs. The useful lives for these intangible assets were determined based upon the remaining period for which the assets were expected to contribute directly or indirectly to future cash flows. Key quantitative assumptions used in the determination of fair value of the developed technology intangible
20

Table of Contents
included revenue growth rates ranging from 3.0% to 55.0%, a discount rate of 17.8% and an assumed technical obsolescent curve of 5.0%.
The carrying value of the remaining assets acquired or liabilities assumed was estimated to equal their fair values based on their short-term nature. These estimates were based on the assumption that the Company believes to be reasonable; however, actual results may differ from these estimates.
MyChem, LLC
On January 27, 2022, the Company completed the acquisition of MyChem, LLC (“MyChem”), a privately-held San Diego, California-based provider of ultra-pure nucleotides to customers in the diagnostics, pharma, genomics and research markets. The acquisition will vertically integrate the Company’s supply chain and expand its product offerings for inputs used in the development of therapeutics and vaccines.
The Company acquired MyChem for a total purchase consideration of $257.9 million, which is inclusive of net working capital adjustments. The total cash consideration was paid using existing cash on hand. The transaction was accounted for as an acquisition of a business as MyChem consisted of inputs and processes applied to those inputs that had the ability to contribute to the creation of outputs.
For the nine months ended September 30, 2022, the Company incurred $3.4 million in transaction costs associated with the acquisition of MyChem, which were recorded within selling, general and administrative expenses in the condensed consolidated statements of operations. For the three months ended September 30, 2022, the Company incurred an insignificant amount of such transaction costs.
The acquisition date fair value of consideration transferred to acquire MyChem consisted of the following (in thousands):
Cash paid (1)
$240,145 
Consideration payable10,000 
Fair value of contingent consideration7,800 
Total consideration transferred$257,945 
____________________
(1)Represents cash consideration paid at closing of $240.0 million and a purchase price adjustment paid in November 2022 of $0.1 million.
Pursuant to the Securities Purchase Agreement (the “MyChem SPA”) between the Company and sellers of MyChem, additional payments to the sellers of MyChem were dependent upon meeting or exceeding defined revenue targets during fiscal 2022 (the “MyChem Performance Payment”). The MyChem SPA provides for a total maximum MyChem Performance Payment of $40.0 million. The MyChem Performance Payment was recorded as contingent consideration and was included as part of the purchase consideration. The Company estimated the fair value of the MyChem Performance Payment contingent consideration based on a Monte-Carlo simulation model which utilized an income approach. The estimated fair value was based on MyChem revenue projections, expected payout term, volatility and risk adjusted discount rates which are Level 3 inputs (see Note 4). The performance period applicable to the MyChem Performance Payment ended as of December 31, 2022 and it was determined that none of the defined revenue thresholds were achieved. Consequently, no payment was made to the sellers of MyChem.
The MyChem SPA also provides that the Company will pay to the sellers of MyChem an additional $20.0 million (the “MyChem Retention Payment”) as of the second anniversary of the closing of the acquisition date as long as two senior employees who are also the sellers of MyChem continue to be employed by TriLink. The Company considers the payment of the MyChem Retention Payment as probable and is recognizing compensation expense related to this payment in the post-acquisition period ratably over the expected service period of two years. For the three and nine months ended September 30, 2023, the Company recorded $1.2 million and $3.0 million, respectively, of compensation expense related to the MyChem Retention Payment within cost of revenue in the condensed consolidated statements of operations. For the three and nine months ended September 30, 2023, the Company recorded $1.3 million and $3.8 million, respectively, of compensation expense related to the MyChem Retention Payment within research and development expenses in the condensed consolidated statements of operations. For the three and nine months ended September 30, 2022, the Company recorded $2.5 million and $6.8 million, respectively, of compensation expense related to the MyChem Retention Payment within research and development expenses in the condensed consolidated statements of operations.
The MyChem SPA further provides that the Company will pay to the sellers of MyChem an additional amount of up to $10.0 million subject to the completion of certain calculations associated with acquired inventory. During the first quarter of 2023, but subsequent to the end of the measurement period, these calculations were completed and a payment of $9.7 million was made by the Company to the sellers. The remaining $0.3 million was recorded as non-cash gain within current year operations.
21

Table of Contents
The following table summarizes the final allocation of the purchase price based upon the fair values of the assets acquired and liabilities assumed at the acquisition date (in thousands):
Cash$1,176 
Current assets2,741 
Intangible assets, net123,360 
Other assets8,585 
Total identifiable assets acquired135,862 
Current liabilities(420)
Other long-term liabilities(8,399)
Total liabilities assumed(8,819)
Net identifiable assets acquired127,043 
Goodwill130,902 
Net assets acquired$257,945 
We recorded the preliminary purchase price allocation in the first quarter of 2022. During the fourth quarter of 2022, we recorded measurement period adjustments resulting in an increase to goodwill of $0.1 million and a decrease to other assets and current liabilities of $0.7 million.
The acquisition was accounted for under the acquisition method of accounting, and therefore, the total purchase price was allocated to the identifiable tangible and intangible assets acquired and the liabilities assumed based on their respective fair values as of the acquisition date. Purchase consideration in excess of the amounts recognized for the net assets acquired was recognized as goodwill. Goodwill is primarily attributable to expanded synergies expected from the acquisition associated with a vertical supply integration. There were no tax impacts associated with the acquisition due to the pass-through income tax treatment of MyChem. All of the goodwill acquired in connection with the acquisition of MyChem was allocated to the Company’s Nucleic Acid Production segment and is deductible to Topco LLC for income tax purposes.
Upon closing of the acquisition, approximately $1.0 million was placed into escrow to cover potential working capital adjustments and approximately $12.5 million was placed into escrow to secure certain representations and warranties pursuant to the terms of the MyChem SPA. These amounts are included in the total purchase consideration of $257.9 million. The Company released the $1.0 million in escrow and paid out an additional $0.1 million related to net working capital adjustments during the fourth quarter of 2022. During the first quarter of 2023, but subsequent to the end of the measurement period, $12.4 million of the amounts in escrow to secure certain representations and warranties was released to the sellers and the remaining $0.1 million was released to the Company for indemnification of pre-closing liabilities, which was recorded within current year operations.
The following table summarizes the estimated fair values of MyChem’s identifiable intangible assets as of the date of acquisition and their estimated useful lives:
Estimated Fair Value
(in thousands)
Estimated Useful Life
(in years)
Trade names$460 3
Developed technology121,000 12
Customer relationships1,900 12
Total$123,360 
The trade name and customer relationship intangible assets are related to MyChem’s name, customer loyalty and customer relationships. The developed technology intangible asset is related to processes and techniques for synthesizing and developing ultra-pure nucleotides. The fair value of these intangible assets was based on MyChem’s projected revenues and was estimated using an income approach, specifically the multi-period excess earnings method. Under the income approach, an intangible asset’s fair value is equal to the present value of future economic benefits to be derived from ownership of the asset. The estimated fair value was developed by discounting future net cash flows to their present value at market-based rates of return utilizing Level 3 inputs. The useful lives for these intangible assets were determined based upon the remaining period for which the assets were expected to contribute directly or indirectly to future cash flows. Key quantitative assumptions used in the
22

Table of Contents
determination of fair value of the developed technology intangible included revenue growth rates ranging from 3.0% to 30.6%, a discount rate of 16.5% and an assumed technical obsolescent curve range of 5.0% to 7.5%.
Pursuant to the terms of the MyChem SPA, the Company recognized an indemnification asset of $8.0 million within other assets, which represented the seller’s obligation to reimburse pre-acquisition income tax liabilities assumed in the acquisition and was recorded within other long-term liabilities.
The carrying value of the remaining assets acquired or liabilities assumed was estimated to equal their fair values based on their short-term nature.
3.Goodwill and Intangible Assets
The Company’s goodwill of $326.0 million and $283.7 million as of September 30, 2023 and December 31, 2022, respectively, represents the excess of purchase consideration over the fair value of assets acquired and liabilities assumed. As of September 30, 2023, the Company had four reporting units, three of which are contained in the Nucleic Acid Production segment. During the nine months ended September 30, 2023, the Company recorded goodwill of $42.4 million in connection with the acquisition of Alphazyme that was completed in January 2023 (see Note 2). As of December 31, 2022, the Company had three reporting units, two of which were contained in the Nucleic Acid Production segment. The Company has not recognized any goodwill impairment in any of the periods presented.
The following table summarizes the activity in the Company’s goodwill by segment for the period presented (in thousands):
Nucleic Acid ProductionBiologics Safety TestingTotal
Balance as of December 31, 2022$163,740 $119,928 $283,668 
Acquisition42,361  42,361 
Balance as of September 30, 2023$206,101 $119,928 $326,029 
Intangible assets are being amortized on a straight-line basis, which reflects the expected pattern in which the economic benefits of the intangible assets are being obtained, over an estimated useful life ranging from 3 to 14 years.
The following are components of finite-lived intangible assets and accumulated amortization as of the periods presented (in thousands):
September 30, 2023
Gross Carrying AmountAccumulated AmortizationNet Carrying AmountEstimated Useful LifeWeighted Average Remaining Amortization Period
(in thousands)(in years)(in years)
Trade names$7,800 $6,214 $1,586 
3 - 10
3.0
Patents and developed technology319,649 103,584 216,065 
10 - 14
9.1
Customer relationships22,313 12,108 10,205 
10 - 12
6.1
Total$349,762 $121,906 $227,856 8.9
December 31, 2022
Gross Carrying Amount
Accumulated Amortization
Net Carrying Amount
Estimated Useful Life
Weighted Average Remaining Amortization Period
(in thousands)(in years)(in years)
Trade names$7,580 $5,746 $1,834 
3 - 10
3.5
Patents and developed technology288,649 85,058 203,591 
10 - 14
9.5
Customer relationships21,853 10,615 11,238 
10 - 12
6.5
Total$318,082 $101,419 $216,663 9.3
During the first quarter of 2023, the Company recorded intangible assets of $31.7 million in connection with the acquisition of Alphazyme that was completed in January 2023 (see Note 2).
23

Table of Contents
The Company recognized $6.2 million and $18.5 million of amortization expense from intangible assets directly linked with revenue-generating activities within cost of revenue in the condensed consolidated statements of operations for the three and nine months ended September 30, 2023, respectively. The Company recognized $5.6 million and $15.9 million of amortization expense from intangible assets directly linked with revenue generating activities within cost of revenue in the condensed consolidated statements of operations for the three and nine months ended September 30, 2022, respectively.
Amortization expense for intangible assets that are not directly related to sales-generating activities of $0.7 million and $2.0 million was recorded as selling, general and administrative expenses for the three and nine months ended September 30, 2023, respectively. Amortization expense for intangible assets that are not directly related to sales generating activities of $0.7 million and $2.2 million was recorded as selling, general and administrative expenses for the three and nine months ended September 30, 2022, respectively.
As of September 30, 2023, the estimated future amortization expense for finite-lived intangible assets were as follows (in thousands):
2023 (remaining three months)
$6,869 
202427,478 
202527,335 
202627,098 
202726,082 
Thereafter112,994 
Total estimated amortization expense$227,856 
4.Fair Value Measurements
The following tables summarize the Company’s financial assets and liabilities that are measured at fair value on a recurring basis by level within the fair value hierarchy as of the periods presented (in thousands):
Fair Value Measurements as of September 30, 2023
Level 1Level 2Level 3Total
Assets
Money market funds
$425,367 $ $ $425,367 
Interest rate cap 13,268  13,268 
Total assets$425,367 $13,268 $ $438,635 
Liabilities
Contingent consideration, non-current$ $ $5,358 $5,358 
Fair Value Measurements as of December 31, 2022
Level 1Level 2Level 3Total
Assets
Interest rate cap$ $11,362 $ $11,362 
Contingent Consideration
In connection with the acquisition of Alphazyme (see Note 2), the Company is required to make contingent payments to the sellers of up to $75.0 million, subject to achieving certain revenue thresholds. The preliminary fair value of the liability for the contingent payments recognized upon the acquisition as part of the purchase accounting opening balance sheet totaled $5.3 million. The preliminary fair value of the contingent consideration was determined using a Monte-Carlo simulation-based model discounted to present value. Assumptions used in this calculation are expected revenue, a discount rate of 17.8% and various probability factors. The ultimate settlement of the contingent consideration could deviate from current estimates based on the actual results of these financial measures. The contingent consideration has three performance payments spanning over three years beginning 2024. This liability is considered to be a Level 3 financial liability that is remeasured each reporting period. Changes in fair value of contingent consideration are recognized as a gain or loss and recorded within change in estimated fair value of contingent consideration in the condensed consolidated statements of operations. During the three and
24

Table of Contents
nine months ended September 30, 2023, the Company recorded increases of $2.4 million and $0.1 million, respectively, in the estimated fair value of contingent consideration. These were due to changes in estimates associated with Alphazyme revenue projections reaching thresholds that would trigger a contingent payment per the Alphazyme SPA.
In connection with the acquisition of MyChem (see Note 2), the Company is required to make contingent payments to the sellers of up to $40.0 million, subject to achieving certain revenue thresholds. The preliminary fair value of the liability for the contingent payments recognized upon the acquisition as part of the purchase accounting opening balance sheet totaled $7.8 million. The preliminary fair value of the contingent consideration was determined using a Monte-Carlo simulation-based model discounted to present value. Assumptions used in this calculation are expected revenue, a discount rate of 16.9% and various probability factors. The ultimate settlement of the contingent consideration could deviate from current estimates based on the actual results of these financial measures. The contingent consideration projected year of payment was 2023. This liability is considered to be a Level 3 financial liability that is remeasured each reporting period. Changes in fair value of contingent consideration are recognized as a gain or loss and recorded within change in estimated fair value of contingent consideration in the condensed consolidated statements of operations. During the second quarter of 2022, the Company recorded a $7.8 million decrease in the estimated fair value of contingent consideration. This was due to a change in the estimate associated with MyChem revenue projections reaching thresholds that would trigger a contingent payment per the MyChem SPA. The contingent consideration expired as of December 31, 2022 and the revenue thresholds were not achieved.
The following table provides a reconciliation of liabilities measured at fair value on a recurring basis using significant unobservable inputs (Level 3) for the period presented (in thousands):
Contingent Consideration
Balance as of December 31, 2021$ 
Contingent consideration related to the acquisition of MyChem7,800 
Change in estimated fair value of contingent consideration(7,800)
Balance as of December 31, 2022 
Contingent consideration related to the acquisition of Alphazyme5,289 
Change in estimated fair value of contingent consideration69 
Balance as of September 30, 2023$5,358 
5.Balance Sheet Components
Inventory
Inventory consisted of the following as of the periods presented (in thousands):
September 30, 2023December 31, 2022
Raw materials$26,787 $13,486 
Work-in-process12,209 21,950 
Finished goods10,146 7,716 
Total inventory$49,142 $43,152 
Other assets
Other assets consisted of the following as of the periods presented (in thousands):
September 30, 2023December 31, 2022
Operating lease right-of-use assets
$62,859 $63,896 
Interest rate cap
13,268 11,362 
Indemnification asset (see Note 2)
6,312 7,682 
Prepaid lease payments 27,253 
Other3,140 5,396 
Total other assets$85,579 $115,589 
25

Table of Contents
6.Government Assistance
Cooperative Agreement
In May 2022, TriLink entered into a cooperative agreement (the “Cooperative Agreement”) with the U.S. Department of Defense, as represented by the Joint Program Executive Office for Chemical, Biological, Radiological and Nuclear Defense on behalf of the Biomedical Advanced Research and Development Authority (“BARDA”), within the U.S. Department of Health and Human Services (“HHS”), to advance the development of domestic manufacturing capabilities and to expand TriLink’s domestic production capacity in its San Diego manufacturing campus (the “Flanders San Diego Facility”) for products critical to the development and manufacture of mRNA vaccines and therapeutics. The Cooperative Agreement has since transitioned from the U.S. Department of Defense to the HHS as of January 2023. The Flanders San Diego Facility consists of two buildings (“Flanders I” and “Flanders II”), however, the Cooperative Agreement is exclusively involved in Flanders I.
The Cooperative Agreement requires the Company to provide the U.S. Government with conditional priority access and certain preferred pricing obligations for a 10-year period from the completion of the construction project for the production of a medical countermeasure (or a component thereof) that the Company manufactures in the Flanders San Diego Facility during a declared public health emergency.
Pursuant to certain requirements, BARDA awarded TriLink an amount equal to $38.8 million or 50% of the construction and validation costs budgeted for the Flanders San Diego Facility. The contract period of performance is May 2022 through January 2034, which is the effective date of the Cooperative Agreement through the anticipated expiration of the 10-year conditional priority access period. Amounts reimbursed are subject to audit and may be recaptured by the HHS in certain circumstances.
During the three and nine months ended September 30, 2023, the Company received $0.3 million and $9.0 million, respectively, of reimbursements under the Cooperative Agreement, with equal offsets recorded to property and equipment on the condensed consolidated balance sheet. During the three and nine months ended September 30, 2022, the Company had not yet received any reimbursements under the Cooperative Agreement. As of September 30, 2023, the Company has recorded a receivable of $3.5 million, with an equal offset to property and equipment.
7.Leases
All of the Company's facilities, including office, laboratory and manufacturing space, are occupied under long-term non-cancelable lease arrangements with various expiration dates through 2038, some of which include options to extend up to 20 years. The Company does not have any leases that include residual value guarantees.
In January 2023, the Company assumed Alphazyme’s existing facility lease in Jupiter, Florida, in connection with the acquisition of Alphazyme (see Note 2). The lease term began in January 2023 and will end in January 2032. The lease is for 10 years with the option to extend for one additional 5-year period.
In February 2023, the Company entered into an agreement to expand the existing Alphazyme facility lease for additional space. The lease term will run concurrently with and as part of the initial lease term.
In March 2023 and June 2023, the Company’s leases for Flanders I and Flanders II, respectively, commenced. The Company entered into the lease agreement in August 2021. The leases are for eleven years with the option to extend for one additional 5-year period. The Company is reasonably certain to execute the renewal option and has, therefore, recognized this as part of its ROU assets and lease liabilities. The lease includes tenant improvement provisions, rent abatement clauses, and escalating rent payments over the life of the lease.
26

Table of Contents
The following table presents supplemental balance sheet information related to the Company's leases as of the periods presented (in thousands):
Line Item in the Condensed Consolidated Balance SheetsSeptember 30, 2023December 31, 2022
Right-of-use assets
Finance leasesProperty and equipment, net$76,656 $ 
Operating leasesOther assets62,859 63,896 
Total right-of-use assets$139,515 $63,896 
Current lease liabilities
Finance leasesCurrent portion of finance lease liabilities$596 $ 
Operating leasesAccrued expenses and other current liabilities7,093 6,269 
Total current lease liabilities$7,689 $6,269 
Non-current lease liabilities
Finance leasesFinance lease liabilities, less current portion$32,077 $ 
Operating leasesOther long-term liabilities49,953 51,556 
Total non-current lease liabilities$82,030 $51,556 
The components of the net lease costs for the Company’s leases reflected in the Company's condensed consolidated statements of operations were as follows for the periods presented (in thousands):
Three Months Ended
September 30,
Nine Months Ended
September 30,
2023202220232022
Finance lease costs:
Depreciation of leased assets$1,370 $ $1,943 $ 
Interest on lease liabilities684  1,015  
Total finance lease costs2,054  2,958  
Operating lease costs3,121 2,480 9,299 6,246 
Variable lease costs1,021 790 2,918 1,858 
Total lease costs$6,196 $3,270 $15,175 $8,104 
The weighted average remaining lease term and weighted average discount rate related to the Company's ROU assets and lease liabilities for its leases were as follows as of the periods presented:
September 30, 2023December 31, 2022
Weighted average remaining lease term (in years):
Finance leases14.4*
Operating leases7.47.9
Weighted average discount rate:
Finance leases8.4 %*
Operating leases6.7 %6.5 %
____________________
*The Company did not have any finance leases as of December 31, 2022.
27

Table of Contents
Supplemental information concerning the cash flow impact arising from the Company's leases recorded in the Company's condensed consolidated statements of cash flows is detailed in the following table for the periods presented (in thousands):
Three Months Ended
September 30,
Nine Months Ended
September 30,
2023202220232022
Cash paid for amounts included in lease liabilities:
Financing cash flows used for finance leases$124 $